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CHAPTER 1: BACKGROUND AND SIGNIFICANCE
Folate
Folic acid, an essential water-soluble B vitamin also known as B9, was first discovered in
the 1940’s. The discovery came to light after the finding that a yeast extract corrected macrocytic
anemia in pregnant women[1]. Most bacteria, yeast and plants can synthesize folates; however,
animals require folate intake through the diet or through supplementation. Folate refers to
compounds that include natural folates and folic acid, with folic acid (FA) referring to the fully
oxidized form[1]. Folic acid, otherwise known as pteroylglutamic acid, was first extracted from
spinach in 1941[2]. Chemical synthesis of folic acid first took place in 1943 by combining a
pteridine ring, paraminobenzoic acid and glutamic acid[3]. Folate is essential for growth,
homeostasis, and plays a critical role in cellular one carbon metabolism. Folate is involved in
maintaining genomic integrity by regulating gene expression through methylation as well as purine
and pyrimidine biosynthesis needed for repair and replication. Folate is also involved in amino
acid metabolism, regeneration of the methyl donor S-adenosyl methionine, the antioxidant
glutathione, as well as various critical cellular functions [4]. Folate deficiency is implicated in the
pathogenesis of multiple diseases and conditions such as anemia, cardiovascular disease, neural
tube defects, neurodegenerative diseases, cancer, and more [5]. Natural folates are found in
adequate quantities in green leafy vegetables as well as legumes, fruits, yeast, and cereals. Animal
food sources contain higher amounts of folates especially in liver and kidney [1].
Absorption
Absorption of folate from the diet occurs mainly in the proximal small intestine [1].
However, recent studies suggest that a significant amount of folate can be absorbed in the colon[6].
Absorption at the brush border occurs via a proton-coupled folate transporter (PCFT) and reduced
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folate carriers (RFC) [1]. RFC is a membrane spanning transport protein that is necessary for the
transport of folates. Some mutations of the gene encoding RFC can lead to alteration of folate and
homocysteine levels [7]. The bioavailability of folates is dependent on multiple factors including
dietary folate content, food sources and preparation methods. Various host factors such as
mutations in the transporters or inflammatory conditions can limit absorption [1]. Folate absorption
can be reduced through passage and destruction in the acidic environment of the stomach.
Surviving folate must be reduced form the polyglutamate form to monoglutamate by folate
conjugase to be absorbed. It is then converted back to the polyglutamate form and stored in the
liver as well as secreted in the bile to be reabsorbed by enterohepatic recirculation [1].
Folate metabolism

DIET
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Folate refers to a diverse array of biological molecules that serve as cofactors in one carbon
transfer and metabolism. Natural folates in the diet and in the body are found predominantly in the
reduced form commonly as 5-methyl-THF [8]. Folic acid, a synthetic folate, must be reduced to
dihydrofolate then further reduced to tetrahydrofolate (THF) by dihydrofolate reductase before
entering the folate cycle. THF is the biologically active form of folate and serves as the starting
point for one carbon transfer. THF picks up one carbon units from the conversion of serine to
glycine catalyzed by the methylentetrahydrofolate dehydrogenase (MTHFD) with the vitamin B6
serving as a cofactor forming N5-N10-methylene-THF. As THF picks up the carbon units it then
can be interconverted between various oxidative states leading to distinct metabolic outcomes. N5N10-methylene THF provides carbon units to thymidylate synthase converting deoxyuridine
monophosphate (dUMP) to deoxythymidine monophosphate (dTMP). Folate plays an essential
role as a cofactor in the de novo biosynthesis of purines, thus maintaining DNA integrity during
DNA synthesis, replication, and repair. N5-N10-methylene-THF is converted to10-formyl-THF,
the most oxidized form of folate used in the de novo synthesis of purines, while 5-methyl-THF is
used in the re-methylation of homocysteine to form methionine, the precursor of Sadenosylmethionine (SAM). SAM is involved in various biological methylations, most
importantly the methylation of DNA and histones and epigenetic imprinting [9]. SAM is converted
back to s-adenosylhomocysteine (SAH) and back to homocysteine. Due to the critical function of
SAM, the SAM/SAH ratio is tightly controlled via numerous metabolic mechanisms and feedback
loops. Dietary factors such as folate and methionine availability can affect SAM/SAH ratio leading
to epigenetic alterations. Homocysteine, long considered to be a marker for various disease
etiologies such as cardiovascular disease and cancer, is regulated by the transulfuration pathway.
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Homocysteine undergoes irreversible degradation to cysteine and ultimately forming the
antioxidant glutathione, an important regulator of cellular redox homeostasis[9].
Folate and neural tube defects
In 1998 the FDA mandated the addition of folic acid (FA) to all enriched cereal grain foods
in order to reduce the incidence of neural tube defects in the offspring of women of childbearing
age [10]. Folate rose to prominence after evidence for interventional trials and observational
studies revealed that periconceptual folate supplementation protected against neural tube defects
(NTD) [5]. This revelation led policymakers, the US health service, and the institute of medicine
to recommend a daily intake of 400 ug folic acid to all women of childbearing age [5]. Soon after,
the FDA mandated the fortification of all flour and uncooked cereal-grain products in the United
States with 140 ug/100g of folic acid by 1998 [11], [12]. Similar recommendations were passed in
Canada, Chile and Western Australia [5].
Argument for fortification
Folate supplementation was seen as safe and beneficial for disease prevention [13]. This
argument was based on abundance of evidence from various studies linking folate deficiency to
various diseases including, anemia, cardiovascular disease, neurological disease, cancer, neural
tube defects (NTD), and low birth weight [13], [14]. Prior to FA fortification, targeted
supplementation with FA in women at risk and of childbearing age failed to yield encouraging
results due to failure to abide to the vitamin regimen. Despite the presence of massive education
and awareness programs, the results did not translate into behavioral changes in the participants
[5]. The risk of non-compliance with the recommendations was augmented by the fact that the
neural tube closes during the fourth week of gestation, a time most women are unaware they are
pregnant. These findings, along with the assumption that folate could provide additional health
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benefits in the general population encouraged health policy advocates to push for generalized folic
acid fortification [5].
Effectiveness of fortification
The goal of the fortification program initiated in 1998 by the FDA was to increase daily
intake of folates by about 100 ug/d while maintaining total intake under 1000 ug/d (safe upper
limit of daily intake) [10]. However, recent studies revealed the predicted increase in folic acid
from fortified food to be much higher (215-240 ug/d) [10]. Fortification lead to an equivalent
decrease of homocysteine [13]. The effect of the fortification on NTD was significant as studies
from the US and Canada showed a reduction of 15-50% in the incidence of NTD [13]. The
dramatic decrease in NTD, however, cannot be solely attributed to the increase in folate levels due
to fortification. Other factors such as improved nutrition and prenatal care had been playing a role
in the steady decrease of NTD even before fortification began[5].
Controversies
For every neural tube defect prevention, several hundred thousand people are exposed to
increased levels and intake of folic acid [15]. Animal studies show that a diet high in folate can
affect DNA and histone methylation leading to epigenetic changes that can be inherited, affecting
successive future generations[15]. Folic acid supplementation can lead to elevated levels of
naturally occurring folates as well as unmetabolized folic acid in the blood [15]. There is currently
a raging controversy among researchers on the risk vs benefit of supplementing the whole
population with high levels of synthetic folates to reduce the risk of comparatively small number
of neural tube defects[15]. In the United kingdom, it is estimated that for every neural tube defect
prevention, there are up to three-quarter million people exposed to extra folic acid with similar
ratios in the united states and Canada [15]. Furthermore, FA interventional studies did not support
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that folate supplementation reduces cardiovascular and stroke risk [13]. The controversies
surrounding FA has led many countries into adopting a more cautious approach to
supplementation[16].
Is Folate harmful?
Folate was deemed generally safe with almost no toxicities [5], however, its use in food
fortification is controversial. High folate intake can mask vitamin B-12 deficiency, a condition
with relatively high prevalence among the geriatric population [17]. Some argue that even
moderate intake is capable of producing a masking effect, prompting several countries to delay or
reject adopting folate fortification mandates [5]. FA intake raises concerns of negative adverse
effects in various subpopulation groups that do not stand to benefit from supplementation [5].
Safety Data for long term exposure to high dose synthetic folates do not exist and is not well
understood [5]. There is mounting evidence that FA may promote the growth and progression of
existing preneoplastic or neoplastic lesions [18]. An increasing percentage of the population is
exposed to folates in levels that exceeds the upper safety limit caused by fortification and
additional supplementation [19]. Folate supplementation can interfere with and reduce the
effectiveness of antifolate based chemotherapy [19]. FA can also interact with prescription drugs
including seizure medications, anti-inflammatory therapies, and malaria medications[15][5]. Other
evidence points to FA supplementation causing genetic instability through epigenetic changes and
selection of disease alleles [20]. High levels of folic acid have been linked to an immune
weakening effect by decreasing natural killer cell cytotoxicity[15]. Furthermore, there is evidence
that folate supplementation to pregnant women can lead to increased risk of insulin resistance and
obesity in their children[15].
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Folate and cancer
The link between folate and cancer was established shortly after folic acid discovery and
extraction [1]. Folate impact on cancer is complex and at times contradictory [18], [19]. After FA
was discovered in the 1940’s, based on limited evidence, researchers attempted to administer FA
to children with leukemia leading to accelerated progression and poor outcomes [13]. Researchers
then learned that the proliferation of leukemia cells is dependent on the availability of the
tetrahydrofolate metabolites leading to the successful use of folate antagonists such as aminopterin
to produce full remission of children with acute leukemia [13]. Conversely, evidence from a
number of studies suggest that folate deficiency can increase the risk of cancer in normal tissues
while adequate folate levels has a protective effect on the risk of developing malignancies of
various tissues [13][21].
There are multiple theories on how folate deficiency can induce carcinogenesis. These
range from folate deficiency causing DNA strand breaks due to uracil misincorporation, alteration
of DNA methylation patterns and gene expression, genomic instability and chromosomal
aberrations [22]–[24]. Others point to impaired DNA repair pathways under folate deficiency, thus
reducing DNA damage threshold and increasing the risk of transformation and mutations with or
without the addition of DNA damage or insult [25]–[28].
More recently, FA fortification was linked to a significant decrease in neuroblastoma
among children, however no change was detected in the incidence of infant acute lymphoblastic
leukemia and hepatoblastoma [13]. A case control study from Germany shows that mothers
supplementing with vitamins containing FA resulted in a decreased risk of non-Hodgkin’s
lymphoma and some types of leukemia in their offspring, however, there was an increased risk of
neuroblastoma [29]. Another study where pregnant women were supplemented with 5mg/day FA
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showed a 70% increase in all cancer mortality and a doubling of breast cancer mortality risk[30].
Kim et al. observed that FA fortification in women who are pregnant or of childbearing age can
potentially reduce the risk of certain childhood cancers in the offspring, however, this comes at
the risk of promoting the growth and progression of undiagnosed, preneoplastic or neoplastic
lesions [19].
Folate and colorectal cancer
Evidence from recent meta-analyses suggest a significant reduction of adenomas and
colorectal cancer (CRC) when comparing subjects of the highest folate status with the lowest [13].
The Nurse’s Health Study showed a 75% reduction in colorectal cancer in women taking
multivitamins with folate [31]. The ASPIRIN/FOLATE polyp prevention study published in 2003
reported that FA supplementation at 1 mg/d had no effect on the recurrence of adenomas. However,
there was a 67% increase in highly malignant advanced lesions at the second follow up [32].
Furthermore, there was a significant increase of other malignancies such as prostate cancer in the
folate supplemented group. Despite a decrease in homocysteine among the FA subjects,
cardiovascular risk was not decreased among the FA supplemented group [32].
Animal studies reveal a dual modulating effect of folate on colorectal cancer whereby the
timing and dosage of folate can have contrasting results [33]. The results show that folate
deficiency increases the risk of transformation, while modest supplementation reduces cancer risk,
and high or supraphysiological doses increase it [13]. Furthermore there is evidence that folate
supplementation can increase CRC risk after the establishment of microscopic neoplastic foci [5].
A possible explanation to this modulation is that folate deficiency in normal tissues can lead to
uracil misincorporation due to the decrease in thymidylate synthesis causing DNA strand breaks,
impaired repair and genomic instability [33]. Furthermore, folate deficiency can lead to aberrant
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DNA methylation due to the possible decrease of S-adenosylmethionine leading to DNA
methylation abnormalities [13]. A folate adequate diet is expected to correct these aberrations
leading to a decrease in cancer risk. However, in preneoplastic or fully transformed lesions, folate
deficiency can inhibit the growth requirements of a rapidly proliferating tissue, leading to
decreased tumor growth and progression. At the same time, FA supplementation can provide the
tumor with nucleotides leading to faster growth [34]. As evident from several studies, FA
supplementation to individuals who might harbor microscopic undiagnosed preneoplastic lesions
can lead to adverse outcomes by fueling cancer growth [32]. It is estimated that 25-50% of people
in the US and Canada may carry asymptomatic adenomas by the age of 50 with the prevalence
increasing with age [13]. Recent large studies reported a nonsignificant trend in total and colorectal
cancer risk due to FA supplementation [13]. In the post fortification era, it is estimated that folate
fortification has added about 200 ug/d FA through enriched products leading to a total intake of
approximately 400 ug/day for non-supplement users and over 800 ug/day in individuals taking
additional supplementation [13]. Other studies pointed out that these are likely to be
underestimates indicating that a significant percentage of the population has high serum
folates[13]. Analysis performed my Mason et al. shows that the United States and Canada had a
reversal in the downward trend in colorectal cancer shortly after the FA mandate. The authors
hypothesized that FA is wholly or partly responsible for the observed reversal in the trend,
however, because of the study design, they could not determine causality [35].
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CRC incidence Post Fortification by Mason et al.[35]

Folate and mTOR
Our early work with folate looked at the impact of folate deficiency on the initiation and
progression of colon cancer in a polymerase  haploinsufficient (-pol+/-) mouse model. We had
originally established that folate restriction negatively impacts DNA base excision repair (BER),
a critical pathway that is required to repair DNA oxidative damage and uracil misincorporation,
by regulating the expression of its rate limiting enzyme -pol [36], [37]. We then hypothesized
that folate restriction in addition to -pol haploinsufficiency will lead to an increased formation of
aberrant crypt foci (ACF), a preneoplastic lesion, in response to the carcinogen dimethylhydrazine
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(DMH). To our surprise, folate restriction in these animals conferred protection under these
conditions (fig1.1) [38]. Analysis of tissue samples via BrdU and TUNEL assays revealed a
decrease in proliferation and an increase in apoptosis in the colon of folate restricted animals [38].
We became interested in understanding how folate restriction (FR) can be protective in our colon
cancer models and if that protection can persist under different conditions and genetic
backgrounds. Analysis of the literature showed that other labs were observing that reduced dietary
folate can confer protection against cancer as well as reducing inflammatory bowel disease in
various lab rodent models [39]–[41]. We were looking for a missing link that can integrate signals
from one carbon metabolism and affect proliferation, apoptosis and cancer, explaining our
findings. Our breakthrough came about when analyzing microarray expression data comparing
folate restricted animals to folate adequate. We saw that folate restriction significantly altered the
expression of genes in the mTOR pathway. Analysis of plasma amino acid levels provided us with
further evidence of the modulating effect of FR on various amino acids, specifically methionine,
isoleucine and leucine. As mTOR is central to the pathways we were investigating, we were
compelled to provide a mechanistic analysis of the effect of folate restriction on mTOR and
colorectal cancer.
The mammalian target of rapamycin also known as the mechanistic target of rapamycin
mTOR is a conserved serine/threonine protein kinase that integrates signals such as growth factors,
amino acids, energy levels, and nutrient availability to modulate cell growth, proliferation,
autophagy, and metabolism. mTOR is found in 2 distinct complexes mTORC1 and mTORC2.
mTORC1 is rapamycin sensitive and is regulated by multiple upstream signals such as growth
factors, amino acid availability, stress and hypoxia, and energy availability [42], [43]. mTORC2
is largely rapamycin insensitive and has different regulators and downstream targets than
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complex1. mTOR became the focus of intensive research in recent years as this signaling pathway
has been altered in various conditions such as cancer, diabetes, and aging [44]. More recently,
mTOR has been found to be modulated by perturbation in one carbon metabolism and more
specifically folate availability [45]. Folate was shown to activate the mTOR pathway via activation
of the AKT pathway, phosphorylating mTOR and the downstream targets p70S6k1 and 4E-BP1
[46]. Furthermore, mTOR was found to be directly linked to one carbon metabolism. Researchers
reported that mTORC1 could control the mitochondrial tetrahydrofolate cycle and induce purine
synthesis as well as stimulate the generation of SAM [47], [48]. Rosario et al. observed that
placing mice on folate free diet for 6 weeks produced marked inhibition of mTORC1 and mTORC2
in various tissues. Further inhibition of downstream targets of both complexes was also observed
as well as decreased activity and expression of the amino acid transporters solute carrier (SLC)
[49]. In other research, Rosario et al. suggested that mTOR may utilize the same amino acids
sensing mechanism for folate sensing [50]. Similar findings linking folate levels to mTOR
signaling, and amino acid transporter activity were confirmed in baboons and humans [49]–[51].
Furthermore, Rosario et al. provided evidence that mTOR can directly regulate folate transporters
trafficking thus regulating cellular folate uptake [52].
mTOR signaling pathway:
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Folate studies
Our lab was interested in understanding how the timing and duration of folate restriction
impacts colon carcinogenesis. Our initial studies in the  haploinsufficient (-pol+/-) mouse model
yielded the surprising result of folate restriction conferring protection against colon cancer
initiation as seen in the reduced numbers of ACF (figure 1.1). To further understand how a folate
depleted diet impacts folate levels over time, we conducted a study with semi synthetic AIN93Gpurified isoenergetic diet. Chow diet was not considered suitable for folate studies as it can contain
variable amounts of folates that range from 2-15mg/kg of diet. Our folate adequate semi synthetic
diet contained 2 mg of folic acid per kg of diet and our folate depleted diet had no added folate.
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Plasma folate decreased in the folate depleted (FD) group by the 3rd day on the diet and no further
decrease was observed after the first week (figure 1.2). On average we observed a 90% decrease
in plasma folate in animals fed FD diets (figure 1.3). The experiment was continued for 12 weeks
and the animals did not exhibit any signs of anemia or pathologies. As a result, we termed this
condition folate restriction rather than folate deficiency. Further pilot studies were conducted to
study the effect of long-term folate restriction. After placing the animals on FD diets for 16 months,
the animals did not display any signs of anemia and looked overall healthier than their FA
counterparts. In a separate study, when we exposed long-term FD diet mice to the carcinogen
dimethylhydrazine (DMH), the animals developed less ACF than the mice fed FA diet. This was
in contradiction to our earlier studies and most published folate restriction studies[53]. It is
important to point out that a review of the literature reveals that most studies investigating the
effect of folate restriction on carcinogenesis place the animals on folate depleted diets for a
relatively short duration before introducing the carcinogenic insult [54]. This short period of
depletion does not allow the animals a chance to acclimate to folate restriction. To confirm the
results, a larger experiment was designed to study the differential effect of the timing and duration
of folate restriction on mice colon carcinogenesis. The animals were fed either a FA (2 mg FA/kg
diet) diet, FR (0 mg FA/kg diet), or FA/FR (7 weeks on FA diet then 1 week on FR diet) for a total
of 8 weeks. Animals were randomly chosen, exposed to DMH, and later sacrificed. As expected,
we saw a significant (90%) decrease in folate levels in both the short term (FA/FR) and long term
(FR) folate restricted groups as compared to controls (figure1.4). Remarkably, long term folate
restriction conferred protection on animals that acclimated to folate restriction for 8 weeks. We
observed that placing the animals on a folate restricted diet for one-week (FA/FR) before initiating
DMH treatment resulted in a significant increase in ACF compared to the folate adequate (FA)
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animals. This finding was consistent with what is reported in the literature and our previous studies.
However, animals on long term Folate restriction (FR) had less ACF in the colon compared to
FA/FR animals (figure 1.5). This observation held true despite measured serum and tissue folate
levels being comparably lower in both folate restricted groups (FA/FR) and (FR) compared to FA.
We were faced with a paradox that begets the question: is all folate restriction disadvantageous
with respect to CRC? And, how can the duration and the timing of folate restriction differentially
impact the critical pathways that run amok in cancer? Furthermore, what other confounders are
present in the standard models and study designs further skewing the results and leading to our
incomplete understanding of the science?
To answer these questions, I began by examining the studies used to assess the effect of
folate restriction on colon carcinogenesis. Many studies including ours resorted to the use of the
antibiotic succinylsulfathiazole (SST) to reduce folate producing bacteria in the gut of the
animals[36], [38]. SST radically alters the composition of the gut microbiome. We wondered if
the use of SST can introduce a confounding element to our studies. The first part of my analysis
addresses the potential of this antibiotic to alter critical pathways known to be affected by folate
status such as mTOR, and oxidative stress. In this study, I analyzed the effect of SST on folate
levels in folate adequate c57Bl/6 male mice fed folate supplemented diet. I did not observe any
significant difference on growth and weight gain at 21 weeks. SST did not significantly affect
folate levels in the plasma, liver and colon tissues of folate adequate mice, however it did alter
energy metabolism and expression of key proteins in the mTOR signaling pathway in the liver.
This research helps shed light on a possible confounding element when using SST to study folate
depletion due to the potential overlap with multiple critical pathways such as mTOR.
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In the second part of the analysis, I will address the findings that the timing and the duration
of folate restriction has a differential effect on colon carcinogenesis. As stated previously, I
observed that long term folate restriction (FR) conferred protection to animals compared to short
term (FA/FR). My research will attempt to elucidate a mechanistic analysis of how short- and longterm folate restriction differentially impact the critical pathway of mTOR, upstream regulators and
downstream targets as well select gene expression analysis. This analysis will be done on animals
with no exposure to the antibiotic SST, therefore, with an intact microbiome.
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Figure 1.1: The effect of folate restriction on colon carcinogenesis in β-pol haploinsufficient mice.
Figure adapted from publication by Lucente et al [38]. WT and β-pol+/− C57BL/6 mice were fed
either a folate-adequate (2 mg FA/kg diet) or a folate-deficient (0 mg FA/kg diet) diet. After 1
week on the respective diets, animals were randomly chosen and were injected with 30 mg/kg
body weight of DMH for 6 weeks. Six weeks after the final injection, animals were sacrificed by
CO2 asphyxiation. The abdominal cavity was opened, and the colon was excised, rinsed with cold
phosphate-buffered saline, cut longitudinally, and fixed flat overnight in 10% neutral buffered
formalin. On the next day, the colonic crypts were stained with 2 g/liter of methylene blue in
phosphate-buffered saline for 5 min. The number of ACF was determined by light microscopy at
×10 magnification in a blinded manner. Bars indicate S.E. (n=6). Different letters indicate
significant differences at P < 0.05.
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Figure 1.1: The effect of folate restriction on colon carcinogenesis in β-pol haploinsufficient mice.
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Figure 1.2: The effect dietary folate restriction on plasma folate levels at various timepoints.
C57BL/6 mice were fed either a folate adequate (FA) or folate depleted (FD) AIN93G-purified
isoenergetic diet (Dyets, Inc., Lehigh Valley, PA) as previously described [32]. The FA group
received a folate adequate diet containing 2 mg of folic acid/kg diet. The FD group received a
folate-deficient diet containing 0 mg of folic acid/kg diet. The animals remained on their respective
diets for the duration of the study. Blood was drawn from the capillary of the eye at various time
points, and folate levels were analyzed using the lactobacillus casei microbiological assay [33].
(FA) represents the average value of folate levels for folate adequate fed mice normalized to 100%.
The FD bars represent the average values of blood folate levels expressed as a percentage of FA
levels at various time points. (n=6 per group). Bars represent S.E.M. Different letters indicate
significant differences at P < 0.05.
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Figure 1.2: The effect dietary folate restriction on plasma folate levels at various timepoints.
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Figure 1.3: The effect of folate in the diet on plasma folate levels in C57BL/6 mice.
The animals were fed either a folate adequate (FA) or folate depleted (FD) AIN93G-purified
isoenergetic diet (Dyets, Inc., Lehigh Valley, PA). The FA group received a folate adequate diet
containing 2 mg of folic acid/kg diet. The FD group received a folate-deficient diet containing 0
mg of folic acid/kg diet. The animals remained on their respective diets for 12 weeks after which
they were sacrificed. Plasma was collected and folate levels were analyzed using a lactobacillus
casei microbiological assay. * Significant differences at P < 0.05.
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Figure 1.3: The effect of folate in the diet on plasma folate levels in C57BL/6 mice.
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CHAPTER 2: SUCCINYLSULFATHIAZOLE MODULATES mTOR SIGNALING
Introduction
The gut microbiome is a complex and diverse array of microorganisms that colonizes the
digestive system. The gut microbiome of humans and other mammals have been extensively
studied due to its profound effect on the health and disease of the host. Perturbations of the gut
microbiome has been linked to various disease etiologies, including: metabolic diseases such as
obesity and type 2 diabetes, autoimmune disorders, inflammation, allergies, cancer, and more[55]–
[63]. The gut microbiota is responsible for producing a plethora of compounds and signaling
molecules that facilitates the complex interactions with its host. These compounds include:
branched chain fatty acids, organic acids, menaquinones (vitamin K), and some B vitamins[64],
[65]. Specifically, the ability of certain bacteria in the gut to synthetize large amounts of folates is
well documented[66], [67]. Others have shown that bacterial folate is easily absorbed and
incorporated into the host folate stores in various tissues[6], [68]–[71]. The amount of folates
produced by a healthy gut flora, specifically through fermentation in the large intestine, is diet
dependent. In fact, diets rich in fermentable fibers have been shown to increase folate levels and
decrease homocysteine in rats, while no effect was observed with non-fermentable fiber
supplemented diets[72].
Other manipulation of the diet, such as the addition of antibiotics, can yield drastic changes
to the gut microbiome[73]–[76]. Specifically, the addition of 1% succinylsulfathiazole (SST), a
long-acting sulfonamide, can produce large shifts in the composition of the gut flora and its ability
to synthetize folate[77], [78]. Succinylsulfathiazole is characterized by its poor absorption and
localized antibacterial activity that is primarily limited to the gut[79]. It was used in the 1940s as
gut antiseptic to lower the bacterial load and prevent infections after gut surgeries[77], [80], [81].
Similar to other sulfonamides in its class, SST works by inhibiting bacterial folate synthesis
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through competitive inhibition with P-aminobenzoic acid (PABA)[82]. SST persists in the gut
much longer than absorbable antibiotics and has no known systemic toxicities[83]. It is hydrolyzed
slowly in the large intestines by bacterial esterases to the active form sulfathiazole[79]. The effect
of SST on gut microbial density and folate production is well documented in earlier studies dating
to the 1940’s[77], [80], [81]. Since then, SST has been replaced clinically by more efficacious and
potent antibiotics. However, researchers have used it extensively in various studies to reduce or
limit the folate producing bacteria in various lab models[36], [84]–[86].
In our studies, we have used SST along with dietary folate restriction to study the impact
of folate depletion on colon cancer initiation[87]. Specifically, we were concerned that the use of
SST to induce a folate deficient status in rodents can modulate some of the same pathways that are
affected by folate depletion. In the present study, we were interested in examining the long-term
effects of SST in the liver of C57BL6 mice fed folate supplemented diets. We analyzed the Impact
of SST on folate levels in serum, colon, and Liver tissues. We were specifically interested in
investigating the effect of the antibiotic on the mTOR signaling pathway, a major growth regulator
that converges signals form growth factors, amino acids, glucose, stress, and energy levels, and
impacts cellular growth, autophagy, and proliferation.
Experimental Procedures
Animals- c57Bl/6 male specific pathogen free mice were purchased from Charles Rivers at 6 weeks
of age (n=3). Animals were maintained in accordance with NIH guidelines for the use and care of
laboratory animals. The Animal protocol was approved by the Wayne State University Animal
Investigation Committee. They were fed the standard mouse chow and water ad libitum and were
maintained on a 12-hr light/dark cycle until the start of the experiment. Mice were anesthetized in
a CO2 chamber and the abdominal cavity was opened for excising the colon and harvesting the
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liver tissue. Blood was obtained by cardiac puncture, centrifuged, and the serum separated. The
harvested liver was flash frozen and stored in liquid nitrogen.
Diets- At 4 months of age, mice were randomly assigned to two dietary groups and fed AIN93Gpurified isoenergetic diets (Dyets, Inc., Lehigh Valley, PA)[88]. Diets were stored at -20°C. The
control group received a folate adequate diet (2mg FA/kg diet for 21 weeks). The experimental
group received a folate adequate diet supplemented with 1% succinyl sulfathiazole (2mg FA/kg
diet + 1% succinyl sulfathiazole for 21 weeks).
Folate Assay- Serum, liver and colon mucosa were collected upon sacrifice. Folate was measured
using the Lactobacillus casei microbiological assay of folic acid derivatives as described by Horne
et. Al[89]. Briefly, growth response of lactobacillus casei to folate availability was measured at
OD 600 nm. A standard curve was used to calculate folate concentrations. Folate levels are
expressed as nmol/g.
Isolation of Whole cell extract- Whole cell extracts were isolated using RIPA buffer. Briefly, 50
mg of liver tissue was homogenized using RIPA buffer (1% Igepal, 0.5% Sodium deoxycholate,
0.1% SDS, 1X PBS) combined with HALT protease inhibitor cocktail (Thermo Fisher). Whole
cell extracts collected were stored at -80°C for further analysis.
Western Blot Analysis- Protein expression analysis was performed using the V3 western blot
system from Bio-Rad. 50 μg of protein was loaded onto criterion TGX stain free precast Gels (BioRad, Hercules, CA). Gels were imaged using chemidoc XRS+ system then wet transferred onto
nitrocellulose membranes. Membranes and Gels were imaged to verify complete transfer.
Manufacturer recommended dilutions of anti-sera developed against various anti-bodies (cell
signaling) were used to detect proteins of interest followed by incubation with HRP-conjugated
secondary antibody (Santa Cruz Biotechnology, Santa Cruz, CA). The bands were visualized and
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quantified using chemidoc XRS+ imager and Image lab software (Bio-Rad, Hercules, CA) after
incubation in SuperSignal West Pico Chemiluminescent Substrate (Pierce Biotechnology,
Rockford, IL). Data are expressed as adjusted band volume normalized to total lane proteins.
Phosphorylated forms of proteins were normalized to total and expressed as ratio.
Gene expression profiling- The mRNA expression levels of various genes were quantified using a
real-time PCR. Total RNA was extracted from liver tissue using RNeasy extraction kit (Qiagen,
Valencia, CA). First strand cDNA was synthesized from 1μg RNA using random primers and polyA primers. Expression of each gene was quantified using real time PCR with specific primers for
the gene. The gene transcript was normalized to GAPDH. External standards for all genes were
prepared by subcloning the amplicons, synthesized using the specific primers into PGEM-T easy
vector. Primer Sequences are listed in Table 2.1.
ATP Assay- ADP/ATP ratio was assessed using a luciferase based bioluminescent assay kit
(Abcam). Briefly, 10 mg of liver tissue was quickly homogenized with nucleotide releasing buffer.
Using a microplate reader, the homogenate was assayed per protocol to determine ATP induced
luminescence. Then ADP converting enzyme was added and luminescence was further
determined. Data are expressed at ADP/ATP ratio.
NAD/NADH Assay- NAD+/NADH was assayed using a fluorometric microplate reader assay
(Abcam). 20 mg of liver tissue was homogenized in provided lysis buffer and supernatant was
collected. Total NAD, NAD+ and NADH were assayed per protocol. Fluorescence was measured
at EX/EM=540/590 nm. Data are expressed at NAD+ to NADH ratio.
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Statistical Analysis- Statistical significance between means was determined using t-test and
analysis of variance followed by post tukey test wherever appropriate. P-values less than 0.05
were considered statistically significant.
Results
Antibiotic in the Diet and its Effect on Weight gain, Serum, Liver and Colon Folate Levels:
The purpose of this study was to analyze the potential confounding effect of antibiotics
used to induce folate depletion in mouse folate studies. Since antibiotics have been used nontherapeutically in animal husbandry to promote weight gain and growth[90], we were interested
in examining the long-term (21 weeks) effect of SST on animal weights. We monitored weight
gain weekly for the duration of the study, however there was no difference after 21 weeks on the
diets (Figure 2.1 a). The animals grew normally and did not exhibit any gross anomalies. We also
did not observe any differences in food consumption (Figure 2.1 b) between the control and
experimental groups.
We were interested in determining whether long term SST alone influences folate levels in
the animals. As expected, we did not observe any significant difference in tissue specific folate
levels between animals fed control (folate supplemented) diet and treated (folate supplemented +
1% SST) diet (Figure 2.1 c). Liver folate levels were highest (control: 48.1 ng/ml, treatment: 53.7
ng/ml) compared to serum (control: 32.7 ng/ml, treatment: 34.1 ng/ml), and colon folate (control:
4.2 ng/ml, treatment: 2.8 ng/ml). This is consistent with findings of previous studies. SST is known
to competitively inhibit folate uptake in the colon due to structural similarities to folic acid,
however we did not see a significant difference in colon folate levels in the AB treated group. In
contrast, animals fed a folate restricted diet with 1% SST for 21 weeks exhibited a significant
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decrease of folate levels in plasma, liver and colon (Figure 2.1 c). Thus, we show here that SST
alone does not significantly affect liver, serum and colon folate levels.
Our lab has previously shown that folate depletion provides protection against colon
carcinogenesis in β-pol haploinsufficient mice[87]. We have also seen that folate status in the diet
alters expression of genes in mTOR signaling (Figure 2.2); a major nutrient sensing pathway that
has been implicated in cancer and aging. Since SST is widely used in folate depletion mouse
studies, it became critical to understand the effect of SST alone on mTOR signaling.
Antibiotic Effect on the PI3K/AKT/mTOR Signaling Pathway:
mTOR, mammalian target of rapamycin, is a conserved serine/threonine protein kinase
downstream of the PI3K/AKT signaling pathway[43]. It is present in two multiprotein complexes
(mTORC1 and mTORC2) and integrates signals from multiple upstream factors such as insulin,
hormones, cytokines, growth factors, stress, hypoxia, glucose, energy and amino acid levels
(Figure 2.3). mTORC1 specifically is a key player in regulating multiple downstream processes
such as cell growth, proliferation and autophagy[91]. mTOR signaling has been shown to be
dysregulated in various cancers and is a key target in multiple life extension strategies[44], [92],
[93]. Since our array data previously showed that mTOR signaling is reduced under FR (Figure
2.2) it became crucial to determine whether SST has a confounding effect on the expression of
proteins in this pathway.
PDK1 (3-phosphoinositide-dependent protein kinase 1) is an upstream activator of
mTORC1 in the IRS-1/PI3K/AKT pathway. It phosphorylates AKT at the Thr308 residue,
inhibiting the TSC1/TSC2 complex and activating mTORC1[94]. mTORC2 on the other hand
phosphorylates AKT (Ser473) as a feedback mechanism activating mTORC1. SST alone
significantly decreases expression of PDK1 protein in our folate adequate model (Figure 2.4 a),
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has no effect on AKT expression (Figure 2.4 b) and significantly decreases phosphorylation of
mTORC1 at the ser2448 residue (Figure 2.4 c-d).
We examined the role of SST and its effect on mTORC1 regulation of protein synthesis
and autophagy (Figure 2.3). The main characterized substrates of mTORC1 in regulating
translation are S6K1 (ribosomal p70 S6 protein kinase) and 4E-BP1 (eukaryotic initiation factor
4E-binding protein 1)[94]. In line with decreased mTORC1 expression, we saw that SST
significantly decreases 4E-BP1 phosphorylation (Figure 2.4 e) but does not influence S6K1
phosphorylation (Figure 2.4 f). We looked at the effect of SST on the expression of autophagy
related proteins Beclin, ATG5 and LCIII and we did not observe any differences (Figure 2.4 g-i).
Observing that SST alters expression of proteins in the PI3K/AKT/mTOR signaling pathway, we
were interested in understanding whether it alters other upstream regulators of TOR signaling,
specifically regulators of stress and energy metabolism.
The effect of SST on upstream regulators of mTOR:
The mTOR signaling pathway is directly altered in response to hypoxia, DNA damage and
energy status[91]. REDD1 (regulated in development and DNA damage response 1) is induced
following exposure to hypoxia, DNA damage and other environmental stresses such as energy
stress and reactive oxygen species[95], [96]. An increase in REDD1 levels lead to the activation
of TSC1/TSC2 complex and inhibition of mTORC1 (Figure 2.3). Interestingly, REDD1 protein
expression in the liver significantly increases in response to SST (Figure 2.5 a), consistent with
the inhibition of mTOR seen (Figure 2.4 c).
The mTOR signaling pathway has also been shown to be altered in response to energy
status[97]. AMPK, a metabolic fuel gauge that detects changes in intracellular AMP/ATP ratio,
directly inhibits mTORC1[98]. It is activated in response to nutrient depletion and acts to maintain
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energy stores by switching on pathways that produce ATP and switching off pathways that
consume ATP[97]. AMPK also enhances SIRT1 activity by increasing cellular levels of NAD+
[99]. NAD cycles between the oxidized (NAD+) and reduced forms (NADH), partaking a central
role in cellular metabolism and energy production. We observed a significant decrease in
ADP/ATP ratio (Figure 2.5 b) and AMPK phosphorylation (Figure 2.5 c) in response to SST.
However, we did not see an effect on SIRT1 expression (Figure 2.6) or NAD+/NADH levels
(Figure 2.5 d) in the SST fed group. Our study sheds light on SST affecting expression of multiple
regulators of mTOR independent of folate status in the diet.
Discussion
Recently, various laboratories began uncovering the complex interactions between the gut
microbiome and the host [56], [58]–[61], [64], shedding new light on the importance of these
microorganisms on the overall health. Antibiotic use in laboratory models can introduce significant
confounding elements to an experiment due in part to the perturbation of the intestinal
microbiome[74], [75], [100].
In our current study, the antibiotic alone did not influence serum and liver folate levels. We
did however see a non-significant decrease in colon folate in the SST group, possibly due to the
localized effect of the antibiotic on the gut flora. Since SST is used to deplete folate in folate
restriction studies directly impacting one Carbon metabolism[36], [84]–[86], we were interested
in looking at the effect of the antibiotic alone on the expression of genes in the transulfuration
pathway. SST did not have a significant effect on the expression of cystathione-beta-synthase
(CBS) the rate limiting enzyme in the transulfuration pathway or on the expression of anti-oxidant
genes (TRX, TRXR, PRDX, OGG1, GPX1, GPX3, SOD and CAT) (Figure 2.6).
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Analysis of cellular energy levels revealed an increase in energy availability (decrease of
ADP/ATP ratio) in SST fed mice. This was consistent with decreased activation of the cellular
energy gauge AMPK. Conversely, we did not observe a change in NAD+/NADH ratio consistent
with SIRT1 mRNA expression.
Analysis of protein expression of targets in the mTOR signaling pathway revealed
decreased activation upstream (PDK1), at both phosphorylated residues of mTOR (ser2448,
ser2481), and at the downstream target (4ebp1). We looked at the expression of a downstream
target of S6K1 important in cell cycle regulation and proliferation, P16[94], but we did not see any
significant difference (Figure 2.6). Interestingly, we saw increased activation of REDD1, an
inhibitor of mTOR signaling that responds to stress and hypoxia. Paradoxically, increased energy
levels leading to the inactivation of AMPK did not result in upregulating mTOR.
Since SST is poorly absorbed, we suspect that the effect we saw is mediated through the
perturbation of the intestinal microflora, where further research is warranted. Recently, the gut
microbiome has been linked to complex interactions that affect almost all physiological functions
including but not limited to metabolism, immunity, inflammation, stress, and cancer [58], [60],
[61], [79]. This research helps shed light on a possible confounding element when using SST to
study folate depletion due to the potential overlap with multiple critical pathways such as mTOR.
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Table 2.1: Primer Sequences

Gene

Forward Primer 5’-3’

Gadd45g AGTTCCGGAAAGCACAGCC
GAPDH
Sirt1
TRXR
GPX1
PRDX6
TRX
OGG1
GPX3
CAT
SOD1
CBS
CTH

AGGATG
GCACAGTCAAGGCCGAGA
TGATTGGCACCGATCCTCG
CTATTCAGCAGAGCGGTTCC
CGAAGTGAATGGTGAGAAG
G
AGCAGGTCCGTAGAAAGAT
CG
CTGATCGAGAGCAAGGAAG
C
CGGCTGGCATCCTAAGACAT
C
CCATTTGGCTTGGTCATTCT
GG
CTACCCGGACACTCACCGCC
AACCAGTTGTGTTGTCAGGA
C
CACAGTGCTGACCAAATCCC
CC
GCTAGAGGCAGCGATTACA
CC

Reverse Primer 5’-3’
GCCAGCACGCAAAAGGTCACATT
GT
ATGGGGGCATCGGCAGA
CCACAGCGTCATATCATCCAG
ACATTCCAAGGCGACATAGG
TCAAAGTTCCAGGCAATGTC
TCAAAGAGAGCCAGTCAGTAGG
TCATCCACATCCACTTCAAGG
AACAGGCTTGGTTGGCGAAGG
TCCCCGTTCACATCTCCTTTC
GGGGCACCACCCTGGTTGTCA
CCACCATGTTTCTTAGAGTGAGG
CACACTTGGCCAAGAGCTCAC
GCAGACATGAAGGTGTTATCTAC
AACC
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Figure 2.1: 1% succinylsulfathiazole (SST) in the diet does not impact weight gain, food intake or
folate levels in folate adequate c57BL/6 mice.
a) Average mouse weights at the beginning of the experiment and after 21 weeks on respective
AIN93G semi synthetic diets (Control= folate adequate diet (2 mg folate/kg diet), Treatment=
folate adequate diet (2 mg folate/kg diet) + SST). b) Average food consumption at the beginning
and at the end of the study. c) Folate levels (nmol/g) in the serum, liver and colon of mice fed
control and treatment diets compared to folate levels in mice fed a folate restricted diet (0 mg
folate/ kg diet) with 1% SST (FR +AB). (n=3). Bars, S.E.M, *P < 0.05.
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Figure 2.1: 1% succinylsulfathiazole (SST) in the diet does not impact weight gain, food intake or
folate levels in folate adequate c57BL/6 mice.
a

b

c

c
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Figure 2.2: Summary of the effect of folate restriction on expression of genes in the mTOR
pathway.
Data adapted from Lucente et al [38]. Gene expression shown as fold change in β-pol+/DMH/folate restricted and WT/folate restricted compared to WT/folate adequate. differentially
expressed genes from colon mucosa were analyzed using the Agilent Whole Mouse Genome
oligonucleotide microarray containing probes for over 41,000 well characterized genes and
analyzed with Agilent Feature Extraction software, version A.5.1.1. The false discovery rate for
FDWT was 5.1%, 1.7% for FDWT DMH treated, and 0.39% for FD β-pol+/− DMH-treated
experimental groups. Gene ontology analysis was performed using the Gene Ontology Tree
Machine (GOTM) (Bioinformatics, Vanderbilt University). Single gene set analysis was
performed, where GOTM compares the distribution of single gene sets in each GO category to
those in an existing reference gene list from the mouse genome, identifying GO categories with
statistically significant enriched gene numbers as determined by the hypergeometric test (p <
0.01).n=4 per group, P<0.01 where value is dispayed; ns, no significant difference
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Figure 2.3: The mTOR signaling pathway.
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Figure 2.4: Succinylsulfathiazole alters expression of proteins involved in the PI3K/AKT/mTOR
signaling in the liver of c57BL/6 mice resulting in an overall decreased mTOR signaling.
Western blot images and quantification of: a-b) phosphorylation of upstream regulators of mTOR
(PDK-1 (ser241) and AKT(ser473)), c-d) mTOR phosphorylation at ser2448 and ser2481 residues,
e-f) phosphorylation of downstream targets of mTOR (4ebp1 (thr37/46) and s6k1(thr421/ser424)),
and g-i) expression of autophagy related proteins (beclin, atg5 and cleaved lc3) in the liver of mice
fed control and treatment diets. Protein expression analysis was performed using the V3 western
blot system from Bio-Rad. Mice were placed on respective AIN93G semi synthetic diets for 21
weeks; Control= folate adequate diet (2 mg folate/kg diet), Treatment= folate adequate diet (2 mg
folate/kg diet) + SST) n=3 per group; Bars, S.E.M., * P < 0.05.
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Figure 2.4: Succinylsulfathiazole alters expression of proteins involved in the PI3K/AKT/mTOR
signaling in the liver of c57BL/6 mice resulting in an overall decreased mTOR signaling.
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Figure 2.5: Effect of SST on upstream regulators of mTOR in the liver of c57BL6 mice. a) Western
blot image and quantification of REDD1 protein expression, b) ADP/ATP ratio, c) western blot
image and quantification of AMPK (thr172) protein phosphorylation and d) NAD+/NADH levels.
n=3 per group,Bars S.E.M., * P < 0.05.
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Figure 2.5: Effect of SST on upstream regulators of mTOR in the liver of c57BL6 mice.

a

b
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Figure 2.6: Effect of SST on relative expression of genes known to be altered by dietary folate
status in the liver of mice (Treatment: Control).
Analysis of mRNA levels in liver of FA SST and FA mice. Mice were placed on respective
AIN93G semi synthetic diets for 21 weeks; Treatment= folate adequate diet (2 mg folate/kg diet)
+ SST), Control= folate adequate diet (2 mg folate/kg diet). Expression of the genes was
determined using a real time PCR technique and the level was normalized to Gapdh expression as
described under “Experimental Procedures”. Data was expressed as box plots representing fold
ratio of treatment/control. No significant differences were observed. n=3 per group; Bars, S.E.M.,
* P < 0.05, Bars S.E.M.
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CHAPTER 3: Timing and Duration of Folate Restriction Differentially Impacts Colon
Carcinogenesis
Introduction
Colorectal cancer (CRC) is the second most common reported cancer in western societies
[101]. The majority of CRC are due to sporadic causes and are not linked to specific mutations
[102]. Diet plays a crucial role in the risk and development of CRC [103]. Notably, folates,
contained in vegetables and leafy greens have been associated with a protective effect [19]. Folate
relevance came to light due to findings that folates reduce NTD, leading to the mandatory
fortification of cereals and grains [11]. Folates are crucial to purines and pyrimidine synthesis, as
well as remethylating homocysteine to methionine [104]. Low dietary folates can lead to uracil
misincorporation in the DNA resulting in double strand breaks, and impaired methylation leading
to genetic instability and inducing transformation [22], [105].
Research into the effect of folate restriction on colon carcinogenesis has yielded conflicting
results. Considerable evidence from the literature suggests that high dietary folates reduced CRC
risk while low folate induces it [33], [106]. However, there have been many discordant results
reported in animal studies and from large epidemiological and case control studies [32], [33], [13],
[5]. These studies raised concerns that the consequences of the mandatory folate fortification could
lead to detrimental outcomes for a large subset of the population.
Our lab previously showed that a folate depleted diet in a -pol haploinsufficient mouse
model provided protection against CRC initiation as seen in reduced incidences of preneoplastic
lesions (ACF) [87]. Others were able to show that folate restriction protected against intestinal
tumorigenesis in various lab rodent models [39]–[41], [107]. In this study, we show that long term
folate restriction protects against initiation of tumorigenesis in male c57Bl/6 mice. We observed
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that placing mice on one week of folate restricted diet before initiating carcinogenic (FA/FR)
treatment produced more ACF compared to animals allowed to acclimate to folate restriction for
8 weeks (FR). Analysis of the mTOR signaling pathway and DNA methyltransferases revealed a
divergent effect between long-term folate restriction FR compared to short-term FA/FR. Our
results indicate that the timing and duration of folate restriction has a differential effect on colon
tumorigenesis.
Experimental procedures
Animals- c57Bl/6 male specific pathogen free mice were purchased from Charles Rivers at 6 weeks
of age. Animals were maintained in accordance with NIH guidelines for the use and care of
laboratory animals. The Animal protocol was approved by the Wayne State University Animal
Investigation Committee. They were fed the standard mouse chow and water ad libitum and were
maintained on a 12-hr light/dark cycle until the start of the experiment. Mice were anesthetized in
a CO2 chamber and the abdominal cavity was opened for excising the colon and harvesting the
liver tissue. Blood was obtained by cardiac puncture, centrifuged, and the serum separated. The
harvested liver was flash frozen and stored in liquid nitrogen.
Diets- At 4 months of age, mice were randomly assigned to two dietary groups and fed AIN93Gpurified isoenergetic diets (Dyets, Inc., Lehigh Valley, PA)[88]. Diets were stored at -20°C. The
control group received a folate adequate diet (2mg FA/kg diet for 8 weeks). The experimental
groups: (FA/FR) received (2mg FA/kg diet for 7 weeks then 0 mg folic acid/kg diet for 1 week for
a total of 8 weeks), and (FR) received a folate deficient diet (0 mg folic acid/kg diet for 8 weeks).
Control and experimental groups were further divided equally into diets supplemented with either
1% of the antibiotic succinylsulfathiazole or antibiotic free diets.
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Carcinogen treatment- After 8 weeks on the respective diets, mice were treated IP with 1, 2dimethylhydrazine HCl (DMH, 30 mg/kg body weight) in 10 mmol/liter of NaHCO3 (Fisher
Scientific) once a week for 6 weeks. The animals were monitored for signs of toxicity and
remained on their respective diets for an additional 7 weeks.
Aberrant crypt foci (ACF) analysis- The excised colons were rinsed with cold phosphate-buffered
saline, cut longitudinally, and fixed flat overnight in 10% neutral buffered formalin. The fixed
colons were stained with 2g/liter of methylene blue in phosphate-buffered saline for 5 mins. The
number of ACF and aberrant crypts per foci were determined by light microscopy at 10X
magnification in a blinded manner as described previously [36], [87]
Folate Assay- Serum, liver and colon mucosa were collected upon sacrifice. Folate was measured
using the Lactobacillus casei microbiological assay of folic acid derivatives as described by Horne
et. Al[89]. Briefly, growth response of lactobacillus casei to folate availability was measured at
OD 600 nm. A standard curve was used to calculate folate concentrations. Folate levels are
expressed as nmol/g.
Isolation of Whole cell extract- Whole cell extracts were isolated using RIPA buffer. Briefly, 50
mg of liver tissue was homogenized using RIPA buffer (1% Igepal, 0.5% Sodium deoxycholate,
0.1% SDS, 1X PBS) combined with HALT protease inhibitor cocktail (Thermo Fisher). Whole
cell extracts collected were stored at -80°C for further analysis.
Western Blot Analysis- Protein expression analysis was performed using the V3 western blot
system from Bio-Rad. 50 μg of protein was loaded onto criterion TGX stain free precast Gels (BioRad, Hercules, CA). Gels were imaged using chemidoc XRS+ system then wet transferred onto
nitrocellulose membranes. Membranes and Gels were imaged to verify complete transfer.
Manufacturer recommended dilutions of anti-sera developed against various anti-bodies (cell
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signaling) were used to detect proteins of interest followed by incubation with HRP-conjugated
secondary antibody (Santa Cruz Biotechnology, Santa Cruz, CA). The bands were visualized and
quantified using chemidoc XRS+ imager and Image lab software (Bio-Rad, Hercules, CA) after
incubation in SuperSignal West Pico Chemiluminescent Substrate (Pierce Biotechnology,
Rockford, IL). Data are expressed as adjusted band volume normalized to total lane proteins.
Phosphorylated forms of proteins were normalized to total and expressed as ratio.
Gene expression profiling- The mRNA expression levels of various genes were quantified using a
real-time PCR. Total RNA was extracted from liver tissue using RNeasy extraction kit (Qiagen,
Valencia, CA). First strand cDNA was synthesized from 1μg RNA using random primers and polyA primers. Expression of each gene was quantified using real time PCR with specific primers for
the gene. The gene transcript was normalized to GAPDH. External standards for all genes were
prepared by subcloning the amplicons, synthesized using the specific primers into PGEM-T easy
vector.
ATP Assay- ADP/ATP ratio was assessed using a luciferase based bioluminescent assay kit
(Abcam). Briefly, 10 mg of liver tissue was quickly homogenized with nucleotide releasing buffer.
Using a microplate reader, the homogenate was assayed per protocol to determine ATP induced
luminescence. Then ADP converting enzyme was added and luminescence was further
determined. Data are expressed at ADP/ATP ratio.
NAD/NADH Assay- NAD+/NADH was assayed using a fluorometric microplate reader assay
(Abcam). 20 mg of liver tissue was homogenized in provided lysis buffer and supernatant was
collected. Total NAD, NAD+ and NADH were assayed per protocol. Fluorescence was measured
at EX/EM=540/590 nm. Data are expressed at NAD+ to NADH ratio.
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Statistical Analysis- Statistical significance between means was determined using t-test and
analysis of variance followed by post tukey test wherever appropriate. P-values less than 0.05
were considered statistically significant.
Results
Study Design and Rationale
Folate requirements in mice is not well defined. It is estimated that the minimum
satisfactory requirement for folic acid based on early mouse studies to be around 0.5 mg/kg diet
[108]. Modern rodent diets add a minimum of 2 mg/kg diet folic acid to the standard formulations
[109]. Chow diets contain variable amounts of folic acid ranging from 2-15 mg/kg diet and
averaging about 8 mg folic acid/kg diet. Mice fed a folate deficient diet experience a quick
reduction in serum folate levels by as much as 60% after 3 days and is further reduced by 90%
after 1 week. Maintaining the animals on a folate deficient diet does not yield any additional
reduction in serum folates after 12 weeks (fig1.3). As a result, rodent studies investigating the
effect of folate restriction typically do not maintain the animals on folate deficient diets for
extended periods. A long-term folate restriction aging study conducted by our lab was able to
maintain the mice on a folate depleted diet for over 32 months with the mice exhibiting better
health and survival than their folate supplemented counterparts (unpublished data). We
hypothesized that the animals might be getting trace amounts of folates from the casein-based
AIN-93G diet as well as a result of gut bacterial fermentation and coprophagy. Since the animals
did not exhibit any signs of anemia in any of our previous experiments, and no further reduction
of serum folate levels was observed after the first week, we termed the condition folate restriction
(FR) rather than folate deficiency (FD). For the purpose of this study, we chose a semi synthetic
AIN-93G diet allowing us to manipulate the formulation while delivering consistency. The control
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group received a folate adequate diet (2mg FA/kg diet for 8 weeks). The experimental groups:
(FA/FR) received 2mg FA/kg diet for 7 weeks then 0 mg folic acid/kg diet for 1 week for a total
of 8 weeks, and (FR) received a folate deficient diet (0 mg folic acid/kg diet for 8 weeks). Control
and experimental groups were further divided equally into diets supplemented with either 1% of
the antibiotic succinylsulfathiazole SST (ABx+) or antibiotic free diets (ABx-) (fig 3.1).
Succinylsulfathiazole (SST), a long-acting sulfonamide, works by inhibiting bacterial folate
synthesis through competitive inhibition with P-aminobenzoic acid (PABA)[82]. After 8 weeks on
the respective diets, mice were treated IP with 1,2-dimethylhydrazine (DMH) once a week for 6
weeks. DMH, an alkylating agent, is a potent colon and liver carcinogen that is extensively used
to model colon carcinogenesis in rodents [110]–[114]. Animals remained on their respective diets
until they were sacrificed at 21 weeks. There was no difference in food consumption and animal
weights between experimental groups and their respective controls at various time points in the
experiment (fig3.2).
Effect of folate restriction on folate levels in plasma, liver, and colon.
Folate levels were measured using the Lactobacillus casei microbiological assay of folic
acid derivatives as described by Horne et. Al[89]. As expected, serum folate levels decreased
significantly as a result of both short (FA/FR) and long-term (FR) diets compared to folate
adequate (FA) diets in both control (CONT) and DMH treated animals (DMH) (fig3.3). The
reduction of serum levels was not significantly different between FA/FR and FR animals. Animals
fed diets containing 1% SST (ABx+) showed a greater decrease in serum folate levels when
compared to mice without the antibiotic (ABx-). DMH had no effect on serum folate levels across
all groups except for the FR DMH ABx+ group, where folate levels were too low to be assayed.
Likewise, we observed an equal and significant reduction in liver folate levels under both FA/FR
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and FR conditions compared to FA. The addition of SST further reduced folate levels in the folate
restricted control groups and more significantly in the DMH treated animals (fig3.4). Analysis of
the folate levels in the colons of control animals revealed a similar pattern to the liver and serum.
Folate levels significantly decreased to the same extent in both FA/FR and FR animals compared
to FA (fig3.5). Animals fed folate deficient diets supplemented with SST experienced a more
pronounced decrease in folate levels in the colons. Folate data were not collected from DMH
animals as the colons were stained for ACF screening. A marked decrease of folates was observed
in the serum of mice fed a folate deficient diet compared to the liver and colon tissues. It was clear
from our analysis that the addition of the antibiotic SST produced a distinct and significant effect
on folate levels in all tissues examined owing to its ability to significantly reduce the number of
folate producing bacteria in the gut. As established previously, since SST perturbs the intestinal
microbiome and potentially confounds our analysis, we conducted all further mechanistic analysis
on non-SST supplemented samples.
Long-term folate restriction protects against preneoplastic lesions initiation
A quick review of the literature regarding the association between folates and colon
carcinogenesis reveals an abundance of data linking low folates to adverse outcomes and cancer
initiation [9], [18], [32], [115]. This view, however, has been challenged by emerging studies
revealing that the relationship between folates and cancer is much more complex than initially
perceived [116]. There is mounting evidence that low folate may protect against spontaneous and
chemically induced cancer [107], [117], [118]. Various epidemiological studies have linked
elevated folates with a higher incidence of several cancers including colon cancer[20], [35], [119].
In this experiment we wanted to assess the effect of the timing and duration of folate restriction on
colon cancer initiation. The colons of mice treated with DMH were screened for the development
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of aberrant crypt foci (ACF), a preneoplastic lesion representing the initial stages of cancer
initiation and development. We established in earlier experiments that folate restriction alone was
insufficient to induce spontaneous preneoplastic lesions in our mouse model. Weekly DMH
injections at 30mg/kg body weight for 6 weeks was adequate to induce ACF in c57Bl/6 mice. 7
weeks after the final injection, the mice were sacrificed, and the colons were stained and scored
for ACF. Consistent with most published studies, we observed that placing the animals on a folate
restricted diet for one week (FA/FR) before initiating the carcinogenic insult resulted in
significantly more ACF compared to animals fed a folate supplemented diet. However, mice
placed on 8 weeks of a folate (FR) depleted diet were protected as evident in significantly less
ACF developed compared to (FA/FR) (Fig3.6). We even observed a non-significant decrease in
the number of ACF when comparing FR to FA. Furthermore, upon sacrifice, we observed major
pathologies in (FA) DMH animals in the form of large gastric tumors, liver nodules, and atrophied
and inflamed colons (fig3.7). Our results show that the timing and duration of folate restriction has
a differential effect on colon cancer initiation. Despite an equal decrease in serum, as well as tissue
folate levels under short (FA/FR) and long-term (FR) folate restriction, FR conferred protection to
c57bl/6 mice that acclimated to a folate restricted diet.
FR modulates the mTOR pathway
Previously

published

studies

from

our

lab

revealed

that

combining

-pol

haploinsufficiency with folate restriction reduces ACF formation [87]. This was concurrent with
decreased proliferation and increased apoptosis in the FR mice. Further studies from our lab
confirmed that long term folate restricted mice had reduced proliferation in the colon compared to
FA. Microarray analysis of the colon provided us with important clues that could uncover the
responsible underlying mechanisms. Interestingly, the expression of the mechanistic target of
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rapamycin (mTOR) was significantly reduced by FR [87] (table 3.2). We became interested in
investigating mTOR as a potential driver behind the effects of folate restriction as a major switch
balancing growth and proliferation with autophagy and apoptosis.
Western blot analysis revealed reduced activation of mTOR in the liver under both FA/FR
and FR as evident in reduced phosphorylation of the ser2448 residue (fig3.11). mTOR is
phosphorylated at ser2448 via the IGF/PI3K/AKT signaling pathway. In DMH treated animals,
FA/FR and FR show a significantly reduced level of mTOR ser2448 phosphorylation compared to
FA mice. No difference is observed in the level of ser2448 phosphorylation between FA/FR and
FR. No difference was observed at the auto phosphorylation site of mTOR, ser2481. This residue
is considered rapamycin insensitive and is not regulated by the IGF/PI3K/AKT signaling cascade
[120][121] (fig3.12). To investigate if mTOR is downregulated through inhibition of the IGF
pathway, we looked at the phosphorylation of PDK1. Phosphorylation of PDK at Ser241 is crucial
for the activation of the AKT pathway and the downstream mTOR target S6k1 [122]. Surprisingly,
in DMH treated animals, we observed a significant increase in phosphorylation of PDK1 in FR,
but not in FA/FR as compared to FA mice. We then looked at REDD1 levels, a marker of hypoxia
and DNA damage. REDD1 regulates mTOR through activation of the inhibitory TSC1/TSC2
complex leading to downregulation of mTOR. REDD1 expression was attenuated in both FA/FR
and FR DMH treated animals as compared to FA DMH (fig3.14). Our finding indicates that mTOR
inhibition is not mediated through IGF/PI3K/AKT or REDD1 signaling.
We had established in earlier experiments that folate restriction disrupts energy pools and
can affect the energy gauge AMPK [123]. AMPK detects changes in the intracellular AMP/ATP
ratio and is activated under nutrient depletion to inhibit anabolic pathways that consume ATP and
induce ATP production [97]. AMPK is an important regulator of mTOR, activating the inhibitory
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TSC1/TSC2 complex as well as directly inhibiting mTOR by phosphorylating the critical binding
subunit raptor [124]. AMPK can neutralize the PI3K activation of mTORC1 as well as enhance
SIRT1 activity by increasing cellular levels of NAD+ (FIG 2.3). ADP/ATP ratio serves as a proxy
indicator for energy availability. In both controls and DMH animals we saw a decrease in the
ADP/ATP ratio in FA/FR compared to FA and FR indicating increased energy availability (fig
3.15). The ratio was significantly increased in both control and DMH FR animals compared to
FA/FR indicating that long term folate restriction has a differential effect on energy pools.
However, looking at AMPK activation through phosphorylation at T172, FA/FR experienced a
significant increase in AMPK phosphorylation in DMH treated mice compared to controls (fig
3.16). FR induced increase in AMPK activation did not reach statistical significance (P=0.1).
Analysis of the NAD+/NADH ratio revealed a non-significant increase (P=0.07) in FR DMH
compared to FA DMH (fig 3.17).
SIRT1 mRNA expression was increased in both FA/FR and FR DMH compared to FA
DMH (fig 3.18). Energy levels, as well as AMPK and SIRT1 activation could potentially explain
the downregulation of mTORC1 under both FA/FR and FR DMH treated animals despite
upregulation of the upstream PI3K/PDK/AKT pathway, however, the results could not explain the
adaptive differential effect that confers protection on long term FR animals.
mTORC1 regulates protein synthesis and growth through the downstream targets 4E-BP1
and S6K1. FA/FR DMH resulted in a decrease in 4E-BP1 phosphorylation at T37-46 compared to
FA DMH, while FR DMH resulted in an additional significant decrease in 4E-BP1
phosphorylation compared to FA/FR and FA DMH (fig 3.19). Analysis of S6K1 phosphorylation
revealed a different picture. FA/FR DMH drastically increased activation and phosphorylation of
S6K1 compared to FA and FR DMH (fig 3.20). S6k1 is a critical downstream target of mTOR that

52

regulates multiple processes such as protein synthesis, cellular metabolism, cell cycle progression,
adipogenesis as well as playing a critical role in cancer [125].
In summary, we saw that mTOR is downregulated under both FA/R and FR potentially due
to the activation of AMPK and SIRT1. However, a divergence of effects was observed downstream
of mTORC1. FR caused a more significant decrease in 4E-BP1 indicating a further reduction in
cap dependent translation. While FA/FR resulted in a significant increase in S6K1 activation
potentially reversing the growth inhibition mediated my repressed mTOR and 4E-BP1.
Effect of FR on methylation
To assess the impact of a short and long-term folate deficient diet on global DNA
methylation, we examined the expression levels of the major DNMT’s involved in generating and
maintaining CpG methylation across the genome. In mammals, DNA methylation is conducted
mainly by DNMT1, DNMT3A, and DNMT3B. During DNA replication and cell division,
DNMT1 conserves and maintains the methylation profile. DNMT3A and DNMT3B, expressed
mainly in undifferentiated cells, are involved in de novo DNA methylation as well as assisting
DNMT1 in maintaining genomic DNA methylation (fig 3.22) [126], [127]. DNMT1 expression
decreased significantly in FA/FR DMH compared to FA DMH and FR DMH (fig3.23). There was
no difference between DNMT1 expression between FR DMH and FA DMH, and a non-significant
decrease in DNMT1 was observed in FR controls compared to FA and FA/FR controls (fig3.23).
Similarly, we saw the same trend with DNMT3A mRNA levels significantly decreased in FA/FR
DMH, but not FR DMH, compared to FA DMH (fig3.24). A non-significant decrease in DNMT3A
expression was also observed in FR controls vs FA controls (fig 3.24). Expression of DNMT3B
was equally significantly decreased in both FA/FR DMH and FR DMH compared to FA DMH
(fig 3.25). Interestingly, DNMT3B expression decreased significantly in FR control compared to
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both FA/FR and FA control. Contrary to reported rodent studies[128], long-term folate restriction
(FR) resulted in decreased DNMT expression (non-significant in DNMT1, P=0.06 in DNMT3A,
significant in DNMT3B) in our control groups. While long-term folate FR DMH had no effect on
DNMT1 and DNMT3A, we observed a significant decrease in DNMT3B compared to FA DMH.
On the other hand, short term folate restriction (FA/FR) did not alter DNMT’s expression in control
animals, but significantly reduced mRNA expression of all 3 DNMT’s as compared to FA DMH.
Our results clearly show that FA/FR has a differential effect on the expression of DNMT’s
compared to FR. These findings could provide us with clues to further investigate the role of DNA
methylation in the adaptive and protective effect of long term-folate restriction.
Discussion
The dichotomy of folic acid
Folate deficiency has been linked to multiple pathologies including: anemia, psychiatric
and neurodevelopmental disorders, cardiovascular disease, adverse pregnancy outcomes, low birth
weight, cancer, and NTD [14], [31], [129], [130]. With the exception of the reduction of NTD,
evidence of folic acid supplementation having a protective effect against these conditions is
inconsistent [131].
Synthetic Folic acid added to food has a higher bioavailability (70-85%) compared to
folates naturally occurring in foods (50%) [10], [132]. The widespread consumption of additional
supplements in the form of vitamins, sports drinks, etc. in addition to fortified foods have caused
a significant percentage of the population to approach or exceed the tolerable upper daily limit of
folates [10], [132]–[134]. In Fact, a survey conducted after the folate mandate revealed that 23%
of the US population, 43% of children under the age of 5 and 38% of elderly persons had high
serum folates. Folic acid, a synthetic variant of natural folate, is converted to the biological form
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(5-methyltetrahydrofolate) as it passes through the intestinal wall thorough a saturable conversion
mechanism, leading to detectable levels of unmetabolized FA [135], [136]. In Fact, following the
folate fortification mandate, unmetabolized folic acid was detected in nearly all serum samples
from US children, adolescents, and adults [137]. Unmetabolized FA can bypass some regulation
in the one carbon cycle by entering as THF rather than 5-methylTHF leading to potentially
detrimental effects [138]. Some point to natural folates having a positive differential effect on
health and disease compared to the synthetic FA [106], [139]. Over the past 2 decades, researchers
have uncovered a trove of information regarding the effects of folates on health and disease.
However, these reports have been often contradictory[106], [140], [141] and have ignited a heated
debate regarding the risks of increasing levels of folates in the population. Of unique importance,
is understanding how folates both natural and supplemented can modulate cancer risk.
Folate and cancer
Folate has a complicated history with cancer. Early publications, following the discovery
of the role of folates in cancer and the subsequent successful use of anti-folate therapy, established
the importance of folate in cancer [142], [143]. Accumulating evidence from various experimental,
clinical and epidemiological studies, suggest that folate deficiency predisposes normal tissues to
carcinogenesis, while folate supplementation suppresses it [34]. However, high doses leading to
supraphysiological concentrations can enhance the growth and progression of cancers in normal
tissues [13], [34]. In the presence of preneoplastic or neoplastic lesions, folate supplementation
can enhance growth and aggressiveness of many cancers [19], [144]. Animal studies reveal a dual
modulating effect of folate on colorectal cancer whereby the timing and dosage of folate can have
contrasting results [33]. Folate deficiency in normal tissues can lead to uracil misincorporation due
to the decrease in thymidylate synthesis causing DNA strand breaks, impaired repair and genomic
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instability [33], [54]. Furthermore, folate deficiency can lead to aberrant DNA methylation due to
the possible decrease of S-adenosylmethionine [13]. A folate adequate diet is expected to correct
these aberrations leading to a decrease in cancer risk. However, in preneoplastic or fully
transformed lesions, folate deficiency can inhibit the growth requirements of a rapidly proliferating
tissue, leading to decreased tumor growth and progression. At the same time, FA supplementation
can provide the tumor with nucleotides leading to faster growth [34].
Animal studies in various rodent models have linked inadequate folate consumption with
an increased risk of cancer, specifically CRC [53], [145], [146]. Others have reached an opposite
conclusion, with many reporting that folate restriction inhibits colorectal tumorigenesis in multiple
models [40], [107], [147]–[149]. The inconsistencies in the results published have made it difficult
to draw a conclusion regarding the effect of folate status on colorectal cancer. With the absence of
a standard model and a multitude of dietary interventions used, it is challenging to draw parallels
across these studies. Rosati et al [54] published a comprehensive review of models and methods
used in studying folate and colorectal cancer in rodents. The studies referenced differed in the use
of animal models, diets, dietary interventions, FA supplementation, antibiotic use, and type of
caging [54]. Of particular importance, the duration and the type of dietary interventions differed
considerably. While folate depleted groups received 0 mg/kg folate, control or supplemented
groups received varying concentrations ranging for 2 mg/kg to 20 mg/kg folate[54]. The duration
of folate depletion, as well as the use of antibiotics and wire-bottom caging to reduce the microflora
and coprophagy supplied folates respectively, impacted serum and tissue specific folate levels
[54]. Data is further confounded by the differential response to folate depletion seen when
comparing rats to mice, as well as between various genotypes of the same species [54].

56

The results of our experiment show unequivocally that within the same mouse genotype,
the duration of folate restriction has a differential effect on colon carcinogenesis initiation under
controlled and identical conditions. The inclusion of the antibiotic SST in part of our experimental
groups allowed us to potentially isolate the effect of the antibiotic on our results and was
documented in chapter 2. We saw that SST further reduced folate levels significantly in most folate
restricted groups (fig 3.3, 3.4, 3.5). This effect translated into a non-significant upward trend in
ACF formation (fig 3.6). Since SST is known to produce a large shift and perturbation in the gut
microbiome, potentially altering various signaling pathways, we decided to conduct further
mechanistic analysis on the non-SST supplemented groups. Our mice were housed in normal
cages, leading to the likelihood of coprophagy. Folate levels form this experiment and previous
data from our lab confirm that the reduction of folate remains constant after the first week on a
folate depleted diet (fig 1.2). Since no observation of anemia or growth inhibition was seen even
when animals remained on the folate depleted diet for several months (unpublished lab data), it is
safe to assume that this condition is not consistent with a severe folate depletion and therefore
considered folate restriction. While we saw a significant (90%) reduction in serum folate levels on
average, the effect on liver and colon was less pronounced, indicating less abundant circulating
folates and greater enrichment and uptake by tissues. Despite comparable levels of folate in serum
and tissue of both FA/FR and FR animals, the acclimation period to folate restriction conferred
protection to these animals. To our knowledge, this constitutes novel findings that has not been
replicated before. Animal studies that previously attempted to pinpoint the effect of folate
restriction on initiation of colon carcinogenesis yielded contradictory results due to the differences
in study design, duration, and timing of folate restriction among other variables [34], [54], [106].
Others showed that folate supplementation is protective initially but then becomes detrimental
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after the establishment of the neoplastic lesion [147]. Hanley et al [107] showed that a temporary
methyl donor depleted diet conferred long-lasting protection against intestinal adenoma by
inducing changes to the intestinal epithelium. Our data suggest that adapting the animals to folate
restriction is likely to induce positive and long-lasting changes to the expression profile of various
tissues. In fact, there is evidence that long term folate restriction can mimic caloric restriction and
potentially increase lifespan [150], [151]. Methionine restriction, another life extension strategy,
requires an adaptation period to exhibit an anti-cancer effect (manuscript in preparation) [152],
[153]. Data from our lab show that long term folate restriction improved survival rate of mice and
modulated mTOR signaling similar to calorie restriction [123].
In humans, a large cohort found that individuals consuming the greatest amount of folate
had a smaller risk of CRC compared the ones consuming the lowest [154]. Other studies could not
conclude that higher folate status is protective [155], while some reported that low folate is
protective [117], [156]. Other studies have linked high FA consumption to increases in the rate of
colon cancer [32], [35]. In a recent large human interventional study, folic acid supplementation
at 1mg/day had no effect on the recurrence of adenomas[32]. On the contrary, upon follow up, the
authors reported a significant increase in advanced lesion with high malignant potential in the FA
groups as well as an increase in overall cancer rates, and no reduction in cardiovascular or stroke
risk [32]. Similar results were published in other large interventional trials were FA did not
improve cardiovascular events [157], and an increased trend in total cancer and colorectal cancer
risk was observed [158]. While several studies indicate that the level of folate levels and intake
after the fortification efforts may be twice as high as originally anticipated [134], Mason et al.
hypothesized that the FA fortification could be wholly or partly responsible for the observed
increase in the colorectal cancer incidence observed in the 1990s [35]. FA has been linked to
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increased risk of prostate and breast cancer [159]–[161]. In a study of FA supplementation in
pregnancy, women receiving 5mg FA/day experienced an 70% increased total cancer mortality
and a doubling of breast cancer mortality compared to women not taking any supplementation
[144]. Furthermore, Troen et al [162] observed that higher levels of FA in elderly women
correlated with reduced cytotoxicity of natural killer cells, a critical part of the immune system
capable of detecting and destroying neoplastic cell clones. However, direct evidence of causality
between high FA and cancer has not been established [163].
The discrepant results from various folate studies have ignited a robust debate regarding the risk
versus benefit of FA supplementation. Some hypothesized that natural folate, not FA is associated
with the protective effect against CRC [34], [119], [138]. While others questioned the validity of
using serum folate versus dietary intake to assess folate exposure [164]. Other modifiers and
confounding elements such as obesity, smoking, alcohol use, gene polymorphism, and B vitamins
status could complicate the necessary analysis [138]. Furthermore, parents’ folate status and the
subsequent effect on epigenetic imprinting can impact the offspring’s cancer risk later in life [138].
Attempting to unravel the complex relationship between folate and cancer can prove to be
quite challenging. Additional layers of complexities are being uncovered as research is progressing
into the matter and we are thrown into a heated discussion regarding the merits of supplementation.
Our research provides another piece of evidence supporting the modulating and sometimes
contradictory effect of folate on health and disease.
Folate and mTOR
mTOR is a conserved serine/threonine protein kinase that integrates signals such as growth
factors, amino acids, energy levels, and nutrient availability to modulate cell growth, proliferation,
autophagy, and metabolism (fig3.10). mTOR is found in 2 distinct complexes mTORC1 and
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mTORC2. mTORC1 is rapamycin sensitive and is regulated by multiple upstream signals such as
growth factors, amino acid availability, stress and hypoxia, and energy availability [42], [43].
mTORc2 is largely rapamycin insensitive with different regulators and downstream targets and is
involved in the mTORC1 signaling feedback as well as regulating the actin cytoskeleton [165].
mTOR controls protein synthesis and ribosome biogenesis through the downstream targets 4EBP1 and P70-S6k1 [166]. mTOR is regulated by and receives input from various upstream
regulators such as AKT, REDD1, AMPK and signaling pathways such as Wnt and Ras. mTOR
became the focus of intensive research in recent years as this signaling pathway has been altered
in various conditions such as cancer, diabetes, and aging [44]. More recently mTOR has been
found to be modulated by perturbation in one carbon metabolism and more specifically folate
availability [45].
Current research has been unraveling the intimate relationship between the one carbon
cycle and mTOR. In fact, mTORC1 was found to induce purine synthesis by controlling the
mitochondrial tetrahydrofolate cycle [47]. mTORC1 was also found to induce the generation of
SAM [48]. Folate deficiency in mice inhibited both mTORC1 and mTORC2 signaling and
downregulated amino acid transporters in a pregnant mouse model as well as human trophoblasts
[51]. Rosario et al. suggests that mTOR senses folate through the proton coupled folate transporter
by modulating the cell surface expression of folate receptor alpha and reduced folate carrier [49],
[51], [167]. Folic acid can activate the PI3K/AKT pathway leading to the phosphorylation of
mTOR and its downstream targets S6K1 and 4E-BP1 [46]. Furthermore, both mTOR and one
carbon cycle are regulated through energy availability. NAD+/NADH ratio, maintained by
mitochondrial oxidative phosphorylation, links energy levels and one carbon cycle through
formate production from serine, as well as regulating mTOR through SIRT1 [9], [168]. Research
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in C. elegans revealed that low levels of folic acid supplementation inhibit mTOR and IGF1 [169].
In vascular smooth muscle cells, FA suppressed mTOR and S6K1 [170]. Others have shown that
folate deprivation can induce cell cycle arrest in neuronal cells via inhibition of IGF-1 signaling
[171]. The seemingly contradictory effects suggest that folate can differentially impact mTOR
depending on the tissue type and conditions.
In our model, we saw that the timing and duration of folate restriction has a divergent effect
on the mTOR signaling pathway. Although both FA/FR and FR downregulation of mTOR were
not mediated by the PI3K/PDK/AKT pathway or REDD1, the perturbation of energy pools and
subsequent activation of AMPK and SIRT1 provided us with a possible mechanistic justification
for mTOR decreased phosphorylation. The equal decrease of mTOR activation under both FA/FR
and FR could not explain the differential effect of these conditions on colon carcinogenesis.
However, analysis of the downstream targets of mTOR, 4E-BP1 and S6K1, revealed a contrasting
difference between the two conditions in DMH treated animals. FR decreased 4E-BP more
significantly than FA/FR indicating a more pronounced inhibition on cap dependent translation,
reducing cell growth and metabolism. Remarkably, FA/FR induced a significant increase in S6k1
phosphorylation, while FR had no effect. S6K1 activation could potentially override the inhibition
on growth and proliferation perpetuated by mTOR [172]–[174]. In fact, mTOR/S6K1 signaling
plays an important role in colorectal carcinoma [175]. S6K1 is able to phosphorylate targets as
rpS6 (ribosomal protein S6), eIF4B (eukaryotic translation Initiation Factor 4B) and eEF2K
(eukaryotic Elongation Factor 2 Kinase), promoting protein synthesis and cell growth [172], [176].
S6K1 can also be activated by TOR-insensitive signaling pathways such as PDK1, MAPK and
SAPK (stress-activated protein kinase) [125], [173]. S6K1 activation contributes to viability,
proliferation, migration and chemo-resistance of various cancers [177]–[179].
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The differential effect of short and long-term folate restriction on 4E-BP1 and S6K1
provided us with crucial evidence to help explain the disparity in the ACF results observed.
However further investigation and research would be needed to confirm and validate the possibility
that the protective effect of folate restriction is mediated through the mTOR pathway.
Folate and methylation
Folate is essential not only for purine and pyrimidine nucleotide synthesis, but also for
maintenance of SAM levels, the universal donor of methyl groups to various methylation reactions
including DNA methylation (fig3.9) [128]. Folate status has a direct and significant effect on DNA
methylation. Perturbances in the folate pools stemming from low or high folate status can result in
hypomethylation or hypermethylation leading to epigenetic instability [180]. DNA methylation
occurs on CpG islands in the promoter regions of genes with the methylation status affecting gene
expression, chromatin modification, and transcription [181]. A number of disease etiologies
including cancer are linked to dysfunctional DNA methylation [131]. Methyl donors include:
folate, B12, betaine, choline and methionine [104]. Critical to maintaining epigenetic imprinting
to DNA, folates became the focus of fortification efforts to reduce the frequency of neural tube
defects [182]. Subject to intense scientific debate, the incidence of many diseases including growth
syndromes, neurological disorders, respiratory disorders, multiple sclerosis, autism, and cancer
increased post fortification [131], [183]. Conversely, diets deficient in methyl donors have been
shown to have deleterious effects [184].
Early animal experiments clearly show that a maternal diet high in methyl donors can alter
epigenetic imprinting by silencing gene mutations in the agouti and Axin alleles [185], [186].
Studies in C57BL/6 mice linked high maternal dietary folate to alteration in the methylome of the
offspring leading to changes in the expression of various genes involved in development as well
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as behavioral changes [187], [188]. Diets low in folate affected methylation patterns of genes
associated with cancer, diabetes, autism and schizophrenia in the sperm of male mice [189].
Combination of the western high fat diet with FA supplementation in mice can potentially induce
heritable susceptibility to diseases such as obesity, type 2 diabetes, and insulin resistance in the
offspring, possibly through epigenetic modification of DNA and histone methylation [131], [190],
[191]. Human studies linked maternal FA supplementation to changes in global methylation
patterns as well as the methylation status of several critical genes affecting birth weight, insulin
resistance, obesity, type 2 diabetes, asthma, and vocabulary development [132], [192]–[197].
DNA hypomethylation is considered an early event in carcinogenesis causing increased
gene expression and DNA strand breaks [181]. In colorectal cancer (CRC), global genomic
hypomethylation is well documented. Additionally, genomic instability, site specific
hypermethylation of tumor suppressor, and mismatch repair genes lead to increased mutations
[128]. Diets deficient in methyl group donors have been shown to upregulate DNA
methyltransferase DNMT in the rat liver [198], [199]. In contrast, folic acid supplementation has
been linked to an increase in DNMT activity [200]. Results from recent studies suggest that
moderate short duration folate deficiency induces DNA hypermethylation in rodent liver, possibly
due to a compensatory upregulation of DNMT [201]–[203]. Others noted that the genomic DNA
methylation in the liver returned to baseline after 8 weeks on folate deficient diet [147]. The effect
of folate restriction on methylation was not consistent across studies. Kim et al. review of the
literature reported that folate restriction affected DNA methylation differently depending on the
severity and length of folate restriction, as well as the use of carcinogenic treatments such as DMH
or AOM [128]. Some argue that aberrant methylation alone could not consistently explain how
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folate restriction could promote carcinogenesis in adults, however, a transgenerational epigenetic
effect could modulate cancer risk in the offsprings [138].
Our results show that long term folate restriction FR produced a more pronounced decrease
in all DNMT’s expression in control animals compared to FA/FR and FR. However, in the DMH
treated animals, the expression levels of DNMT1 and DNMT3A in FR animals were equivalent to
that of FA, while in FA/FR both were significantly reduced. This suggests that animals adapted to
long term folate restriction and then exposed to DMH mimic FA in the expression of critical
maintenance methyltransferases. This is consistent with the findings by song et al. [147] noting an
adaptive rebound of genomic DNA methylation. The differential effect of FR compared to FA/FR
on DNA methyltransferase expression represents a valid target for further analysis to fully
characterize the impact on global methylation as well as on gene specific methylation patterns.
Our research provides yet another evidence of the increasingly complex and puzzling
effects of folate. This data shows, for the first time in a controlled experiment, that adapting to
long term folates restriction can provide a protective effect against colon cancer. We show that
long-term folate restriction impacts critical pathways, such as mTOR and methylation, differently
than short-term. While more research is needed to unravel the complex dynamics of this observed
protection, our results provides us with important leads. The significance of these findings is that
it overturns many of the rigid assumptions we had about the role of folates in CRC, revealing a
much more complicated picture indeed.
It is quite clear that the discourse regarding the effects of folate on health and disease will
not be settled any time soon. In fact, results from the last decades of research regarding the
relationship between folate and cancer have added to the confusion and complexity surrounding
the subject. This fact does not detract from the importance of the issue at hand. On the contrary, it

64

delivers a great sense of urgency to pursue vital research and attempt to unravel the mystery. As a
greater percentage of the population is exposed to elevated levels of folates (both natural and
synthetic), a condition that may be considered anomalous from an evolutionary perspective, we
are faced with a difficult conundrum. Do we continue with the efforts to supplement the whole
population with FA to prevent a limited number of neural tube defects while risking a much larger
and vulnerable segment of the population? Our incomplete understanding of the subject prevents
us from providing a definitive answer. Furthermore, it could take decades more for a clear
consensus to emerge. Further action could be delayed by bureaucracy and policy implementation.
By that time, the potential deleterious effects would have impacted generations as well as their
offspring.
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Figure 3.1: Study design
Sixty 4 months old C57BL/6 male mice were randomly assigned to 6 groups and fed AIN93Gpurified isoenergetic diets (Dyets, Inc., Lehigh Valley, PA)[88]. The control group (FA) received
a folate adequate diet (2mg FA/kg diet for 8 weeks) +/- ABx (antibiotic SST). The experimental
groups: (FA/FR) received (2mg FA/kg diet for 7 weeks then 0 mg folic acid/kg diet for 1 week for
a total of 8 weeks) +/- ABx (antibiotic SST), and (FR) received a folate deficient diet (0 mg folic
acid/kg diet for 8 weeks) +/- ABx (antibiotic SST). After 8 weeks on the respective diets, 6-7 mice
from each group were randomly chosen and treated IP with 1, 2-dimethylhydrazine HCl (DMH,
30 mg/kg body weight) in 10 mmol/liter of NaHCO3 (Fisher Scientific) once a week for 6 weeks.
The animals were monitored for signs of toxicity and remained on their respective diets for an
additional 7 weeks before sacrifice. Control n=3, DMH n=6-7.
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Figure 3.1: Study design
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Figure 3.2: The effect of short-term and long-term folate restriction with/without antibiotic on
animal weights in control and DMH treated animals
Weights of FA, FA/FR, and FR mice +/- ABx (antibiotic SST) at the beginning of the experiment,
after 8 weeks on respective diets, and at the time of sacrifice (21 weeks). Control n=3, DMH n=67. Bars S.E.M

68

Figure 3.2: The effect of short-term and long-term folate restriction with/without antibiotic on
animal weights in control and DMH treated animals
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Figure 3.3: The effect of short-term and long-term folate restriction with/without antibiotic on
serum folate levels in control and DMH treated animals
Folate levels were analyzed using the Lactobacillus casei microbiological assay of folic acid
derivatives as described by Horne et. Al[89]. Serum folate levels are expressed as ng/ml. FA:
Folate adequate, FA/FR: short-term Folate restriction, FR: long-term Folate Restricted, ABx+: diet
with 1% SST, ABx-: diet without 1% SST. Control n=3, DMH n=6-7. Different letters indicate
significant differences at P < 0.05.
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Figure 3.3: The effect of short-term and long-term folate restriction with/without antibiotic on
serum folate levels in control and DMH treated animals
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Figure 3.4: The effect of short-term and long-term folate restriction with/without antibiotic on liver
folate levels in control and DMH treated animals
Folate levels were analyzed using the Lactobacillus casei microbiological assay of folic acid
derivatives as described by Horne et. Al[89]. Folate levels are expressed as nmol/g. FA: Folate
adequate, FA/FR: short-term Folate restriction, FR: long-term Folate Restricted, ABx+: diet with
1% SST, ABx-: diet without 1% SST. Control n=3, DMH n=6-7. Different letters indicate
significant differences at P < 0.05.
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Figure 3.4: The effect of short-term and long-term folate restriction with/without antibiotic on liver
folate levels in control and DMH treated animals
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Figure 3.5: The effect of short-term and long-term folate restriction with/without antibiotic on
colon folate levels in control animals
Folate levels were analyzed using the Lactobacillus casei microbiological assay of folic acid
derivatives as described by Horne et. Al[89]. Folate levels are expressed as nmol/g. FA: Folate
adequate, FA/FR: short-term Folate restriction, FR: long-term Folate Restricted, ABx+: diet with
1% SST, ABx-: diet without 1% SST. n=3. Different letters indicate significant differences at P <
0.05.
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Figure 3.5: The effect of short-term and long-term folate restriction with/without antibiotic on
colon folate levels in control animals

75

Figure 3.6: Long-term folate restriction protects against ACF formation
Aberrant Crypt Foci (ACF) numbers in the colons of DMH treated mice were determined by light
microscopy at 10x magnification in a blinded manner as described in material and methods. Image
I represent a normal colon with no pathologies. Image III shows a preneoplastic aberrant crypt foci
that displays as a raised area in the center. Highlighted samples refer to animals that exhibited
large cancerous growths and gross abnormalities in the stomach and liver upon sacrifice. FA:
Folate adequate, FA/FR: short-term Folate restriction, FR: long-term Folate Restricted, ABx+: diet
with 1% SST, ABx-: diet without 1% SST. n=6-7. Different letters indicate significant differences
at P < 0.05.
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Figure 3.6: long-term folate restriction protects against ACF formation
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Figure 3.7: Gross abnormalities in FA DMH animals
The following images refer to cancerous growths and pathologies uncovered in animals in the
Folate supplemented (FA) DMH animals.
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Figure 3.7: Gross abnormalities in FA DMH animals
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Figure 3.8: The timing and duration of folate restriction has a differential effect on the occurrence
of preneoplastic lesions ACF
Top figure: Folate levels were analyzed using the Lactobacillus casei microbiological assay of
folic acid derivatives as described by Horne et. Al[89]. Serum folate levels are expressed as ng/ml.
Bottom figure: Aberrant Crypt Foci (ACF) numbers in the colons of DMH treated mice were
determined by light microscopy at 10x magnification in a blinded manner.
FA: Folate adequate, FA/FR: short-term Folate restriction, FR: long-term Folate Restricted,
ABx+: diet with 1% SST, ABx-: diet without 1% SST. DMH n=6-7. Different letters indicate
significant differences at P < 0.05.
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Figure 3.8: The timing and duration of folate restriction has a differential effect on the occurrence
of preneoplastic lesions ACF
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Figure 3.9: Folate metabolism and one carbon cycle
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Table 3.1: Folate restriction alters plasma amino acids
Plasma was collected from C57BL/6 mice fed (FA) folate adequate diet (2 mg folic acid/kg diet)
and (FR) folate restricted diet (0 mg folic acid/kg diet) upon sacrifice. Data obtained from 4 mice
in each group. Samples were sent to MSU and UC-Davis for HPLC analysis. Amino aicd levels
are expressed as ratio of FR to FA.
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Table 3.2: Effect of folate restriction on mTOR pathway genes.
Total RNA was isolated from the colon mucosa of folate adequate and folate restricted mice using
the RNeasy Mini Kit (Qiagen, Valencia, CA) per manufacturer's protocol. RNA samples were
quantified with NanoDrop ND-1000 (NanoDrop Technologies, Inc, Wilmington, DE) and 260/280
ratio in the range of 2.0-2.2 was defined as acceptable. A quality check of the total RNA was
performed using an Agilent 2100 Bioanalyzer (Agilent Technologies, Palo Alto, CA). Microarray
expression profiling was conducted by Microarray & Bioinformatics Facility Core at Wayne State
University (Institute of Environmental Health Sciences, Detroit, MI) according to the
manufacturer’s protocol. Data obtained from 4 mice in each group. Significant differences at P <
0.01.
FR
as
compared
to
FA.
ns:
not
significant
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Figure 3.10: Folate restriction reduces mTOR phosphorylation at the serine 2448 residue
The level of mTOR protein phosphorylation at serine 2448 was analyzed using western blotting
as described in materials and methods. Data is expressed as adjusted band volume normalized to
total lane proteins. Levels of phosphorylated protein were determined first, then the membrane
lightly stripped and tested for respective total protein. Phosphorylated levels of protein were
normalized to total and expressed as ratio. FA: Folate adequate diet, FA/FR: short-term Folate
restricted diet, FR: long-term Folate restricted diet, CON: control mice, DMH: mice treated with
dimethylhydrazine, ABx-: diet without 1% SST. Control n=3, DMH n=6-7. * Significant
differences at P < 0.05.
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Figure 3.10: Folate restriction reduces mTOR phosphorylation at the serine 2448 residue
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Figure 3.11: Effect of folate restriction on mTOR auto phosphorylation at the serine 2481 residue
The level of mTOR protein phosphorylation at serine 2481 was analyzed using western blotting
as described in materials and methods. Data is expressed as adjusted band volume normalized to
total lane proteins. Levels of phosphorylated protein were determined first, then the membrane
lightly stripped and tested for respective total protein. Phosphorylated levels of protein were
normalized to total and expressed as ratio. FA: Folate adequate diet, FA/FR: short-term Folate
restricted diet, FR: long-term Folate restricted diet, CON: control mice, DMH: mice treated with
dimethylhydrazine, ABx-: diet without 1% SST. Control n=3, DMH n=6-7. * Significant
differences at P < 0.05.
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Figure 3.11: Effect of folate restriction on mTOR auto phosphorylation at the serine 2481 residue
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Figure 3.12: Effect of folate restriction on PDK1 phosphorylation at the serine 241 residue
The level of PDK1 phosohoryation was analyzed using western blotting as described in materials
and methods. Data is expressed as adjusted band volume normalized to total lane proteins. Levels
of phosphorylated protein were determined first, then the membrane lightly stripped and tested for
respective total protein. Phosphorylated levels of protein were normalized to total and expressed
as ratio. FA: Folate adequate diet, FA/FR: short-term Folate restricted diet, FR: long-term Folate
restricted diet, CON: control mice, DMH: mice treated with dimethylhydrazine, ABx-: diet without
1% SST. Control n=3, DMH n=6-7. * Significant differences at P < 0.05.
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Figure 3.12: Effect of folate restriction on PDK1 phosphorylation at the serine 241 residue
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Figure 3.13: Effect of folate restriction on REDD1 protein expression
The level of REDD1 protein expression was analyzed using western blotting as described in
materials and methods. Data is expressed as adjusted band volume normalized to total lane
proteins. FA: Folate adequate diet, FA/FR: short-term Folate restricted diet, FR: long-term Folate
restricted diet, CON: control mice, DMH: mice treated with dimethylhydrazine, ABx-: diet without
1% SST. Control n=3, DMH n=6-7. * Significant differences at P < 0.05.
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Figure 3.13: Effect of folate restriction on REDD1 protein expression
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Figure 3.14: Effect of folate restriction on energy levels (ADP/ATP ratio)
ADP/ATP ratio was assessed using a luciferase based bioluminescent assay kit (Abcam). 10 mg
of liver tissue was quickly homogenized with nucleotide releasing buffer. Using a microplate
reader, the homogenate was assayed per protocol to determine ATP induced luminescence. Then
ADP converting enzyme was added and luminescence was further determined. Data are expressed
at ADP/ATP ratio. FA: Folate adequate diet, FA/FR: short-term Folate restricted diet, FR: longterm Folate restricted diet, CON: control mice, DMH: mice treated with dimethylhydrazine, ABx: diet without 1% SST. Control n=3, DMH n=6-7. * Significant differences at P < 0.05.
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Figure 3.14: Effect of folate restriction on energy levels (ADP/ATP ratio)
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Figure 3.15: Effect of folate restriction on AMPK phosphorylation at T172 residue
The level of AMPK protein phosphorylation at threonine 172 was analyzed using western blotting
as described in materials and methods. Data is expressed as adjusted band volume normalized to
total lane proteins. Levels of phosphorylated protein were determined first, then the membrane
lightly stripped and tested for respective total protein. Phosphorylated levels of protein were
normalized to total and expressed as ratio. FA: Folate adequate diet, FA/FR: short-term Folate
restricted diet, FR: long-term Folate restricted diet, CON: control mice, DMH: mice treated with
dimethylhydrazine, ABx-: diet without 1% SST. Control n=3, DMH n=6-7. * Significant
differences at P < 0.05.
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Figure 3.15: Effect of folate restriction on AMPK phosphorylation at T172 residue
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Figure 3.16: Effect of folate restriction on energy levels (NAD+/NADH ratio)
NAD+/NADH ratio was assayed using a fluorometric microplate reader assay (Abcam). 20 mg of
liver tissue was homogenized in provided lysis buffer and supernatant was collected. Total NAD,
NAD+ and NADH were assayed per protocol. Fluorescence was measured at EX/EM=540/590
nm. Data is expressed at NAD+ to NADH ratio. FA: Folate adequate diet, FA/FR: short-term
Folate restricted diet, FR: long-term Folate restricted diet, CON: control mice, DMH: mice treated
with dimethylhydrazine, ABx-: diet without 1% SST. Control n=3, DMH n=6-7. * Significant
differences at P < 0.05.
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Figure 3.16: Effect of folate restriction on energy levels (NAD+/NADH ratio)

98

Figure 3.17: Effect of folate restriction on SIRT1 mRNA expression
Levels of SIRT1 mRNA were analyzed in the liver. Expression of the gene was determined using
real time PCR technique and the level was normalized to Gapdh expression as described in
materials and methods. FA: Folate adequate diet, FA/FR: short-term Folate restricted diet, FR:
long-term Folate restricted diet, CON: control mice, DMH: mice treated with dimethylhydrazine,
ABx-: diet without 1% SST. Control n=3, DMH n=6-7. * Significant differences at P < 0.05.
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Figure 3.17: Effect of folate restriction on SIRT1 mRNA expression
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Figure 3.18: Effect of folate restriction on 4E-BP phosphorylation at T37-46 residues
The level of 4E-BP1 protein phosphorylation at T37-46 was analyzed using western blotting as
described in materials and methods. Data is expressed as adjusted band volume normalized to total
lane proteins. Levels of phosphorylated protein were determined first, then the membrane lightly
stripped and tested for respective total protein. Phosphorylated levels of protein were normalized
to total and expressed as ratio. FA: Folate adequate diet, FA/FR: short-term Folate restricted diet,
FR: long-term Folate restricted diet, CON: control mice, DMH: mice treated with
dimethylhydrazine, ABx-: diet without 1% SST.Control n=3, DMH n=6-7. * Significant
differences at P < 0.05.
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Figure 3.18: Effect of folate restriction on 4E-BP phosphorylation at T37-46 residues

102

Figure 3.19: Effect of folate restriction on P-70 S6K1 phosphorylation
The level of P-70 S6K1 protein phosphorylation was analyzed using western blotting as described
in materials and methods. Data is expressed as adjusted band volume normalized to total lane
proteins. Levels of phosphorylated protein were determined first, then the membrane lightly
stripped and tested for respective total protein. Phosphorylated levels of protein were normalized
to total and expressed as ratio. FA: Folate adequate diet, FA/FR: short-term Folate restricted diet,
FR: long-term Folate restricted diet, CON: control mice, DMH: mice treated with
dimethylhydrazine, ABx-: diet without 1% SST. Control n=3, DMH n=6-7. * Significant
differences at P < 0.05.
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Figure 3.19: Effect of folate restriction on P-70 S6K1 phosphorylation
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Figure 3.20: P-70 S6K1 signaling cascade and feedback mechanisms

Source:[204]
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Figure 3.21: DNA methyltransferases role in methylation
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Figure 3.22: Effect of folate restriction on DNMT1 mRNA expression
Expression of DNMT1 mRNA was analyzed in the liver tissues. Expression of the gene was
determined using Real Time PCR technique and the level was normalized to Gapdh expression as
described in materials and methods. Experiments were conducted in technical triplicates. FA:
Folate adequate diet, FA/FR: short-term Folate restricted diet, FR: long-term Folate restricted diet,
CON: control mice, DMH: mice treated with dimethylhydrazine, ABx-: diet without 1% SST.
Control n=3, DMH n=6-7. * Significant differences at P < 0.05
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Figure 3.22: Effect of folate restriction on DNMT1 mRNA expression
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Figure 3.23: Effect of folate restriction on DNMT3a mRNA expression
Expression of DNMT3a mRNA was analyzed in the liver tissues. Expression of the gene was
determined using Real Time PCR technique and the level was normalized to Gapdh expression as
described in materials and methods. Experiments were conducted in technical triplicates. FA:
Folate adequate diet, FA/FR: short-term Folate restricted diet, FR: long-term Folate restricted diet,
CON: control mice, DMH: mice treated with dimethylhydrazine, ABx-: diet without 1% SST.
Control n=3, DMH n=6-7. * Significant differences at P < 0.05
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Figure 3.23: Effect of folate restriction on DNMT3a mRNA expression
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Figure 3.24: Effect of folate restriction on DNMT3b mRNA expression
Expression of DNMT3b mRNA was analyzed in the liver tissues. Expression of the gene was
determined using Real Time PCR technique and the level was normalized to Gapdh expression as
described in materials and methods. Experiments were conducted in technical triplicates. FA:
Folate adequate diet, FA/FR: short-term Folate restricted diet, FR: long-term Folate restricted diet,
CON: control mice, DMH: mice treated with dimethylhydrazine, ABx-: diet without 1% SST.
Control n=3, DMH n=6-7. * Significant differences at P < 0.05
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Figure 3.24: Effect of folate restriction on DNMT3b mRNA expression
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CHAPTER 4: SUMMARY AND FUTURE DIRECTIONS
The relation between folate and cancer is growing increasingly complex as research is
uncovering new facts that contradict the existing paradigm. For the past several decades the
collective evidence supported the increased intake of folates to improve health outcomes and
protect against various cancers, specifically colon cancer [26]. Folate’s role in nucleotide synthesis
was well known since the 40’s and that knowledge led to the rise of the antifolate class of drugs to
treat various cancers [142]. Adequate folate is also considered essential for maintaining genetic
stability and protecting tissues from transformation. However, overly abundant consumption of
folates can encourage the growth of dysplastic neoplastic lesions [106]. The mandatory
fortification of grains and cereals with folates to reduce NTD’s since the 90’s led to a substantial
increase in the population’s folate levels [10].
Animal studies assessing the risks and benefits of folate supplementation provided
contradictory findings [54]. Our initial findings uncovering a protective effect of dietary folate
restriction on colon carcinogenesis in our β-pol haploinsufficient model led us to expand our
investigation to see if the protection persists in normal mouse genetic background [38]. Our initial
pilot studies revealed that extended folate restriction, allowing the animals to acclimate, provided
protection as seen in reduced ACF formation. We then embarked on this current study to further
characterize and attempt to mechanistically dissect that protective effect. We randomized our
experimental and control mice in groups with or without the antibiotic succinylsulfathiazole. SST
is commonly used to reduce folate producing bacteria in the gut of the animals and can therefore
induce a more severe folate depleted condition. We were also interested in isolating the effect of
the antibiotic in a folate adequate condition to see if it can modify or confound the suspected
pathways modulated by folate restriction and cancer. Surprisingly, SST had a significant effect on
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the mTOR pathway, reducing mTOR phosphorylation and the downstream target 4E-BP1.
Furthermore, we saw a decrease in IGF1 activation upstream of mTOR as evident from reduced
PDK1 phosphorylation. Paradoxically, SST increased energy levels leading to decreased
activation of the mTOR inhibitor AMPK. However, REDD1, an inhibitor of mTOR that responds
to stress and hypoxia was increased by SST.
Summary of the effect of SST on the mTOR pathway:

These findings allowed us to characterize the effect of SST on the critical mTOR pathway.
The observed effects most likely stemmed from the perturbation of intestinal flora leading to the
disruption of growth signaling and energy metabolism. SST groups were then omitted from further
mechanistic analysis in the 2nd part of the study.
After establishing that an intact microflora is crucial for a sound analysis of the effect of
folate restriction on colon carcinogenesis, we proceeded with analysis of the remaining groups that
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were not exposed to SST. The results clearly show that in c57/bl6 mice, carcinogenic treatment
initiated one week after starting a folate depleted diet caused significantly more ACF than a folate
depleted diet for 8 weeks when compared to FA control. This effect was observed despite an equal
reduction in serum, liver and colon folate levels between FA/FR and FR mice. That brings us to
the conclusion that folate restriction requires an adaptation period to exert a protective effect.
Analysis of the mTOR pathway revealed that both FA/FR and FR reduced mTORC1 activation.
However, we observed a paradoxical activation of the IGF1 pathway upstream of mTORC1 though
increased activation of PDK1. REDD1 expression was decreased in both FA/FR and FR. mTORC1
downregulation was likely induced by perturbance in energy levels and metabolism as seen by the
increased expression of AMPK and SIRT1. We observed a differential effect between FR and
FA/FR downstream of mTOR. 4E-BP1 phosphorylation was significantly reduced in FR compared
to FA/FR and FA, while S6K1 phosphorylation was significantly increased in FA/FR compared
to FA and FR. These findings suggest that long term folate restriction FR may potentially inhibit
growth and metabolism, a condition that is considered protective against cancer initiation and
progression. While short term folate restriction resulted in a paradoxical increase in S6K1
activation, potentially overriding the growth inhibition of mTORC1 downregulation. Analysis of
the DNA methyltransferases revealed that FA/FR resulted in decreased expression of DNMT1 and
DNMT3a compared to FA, while FR had no effect. The decrease in the activity of
methyltransferases in FA/FR warrants additional research to fully characterize the impact on
genomic methylation patterns.

115

Summary of the differential effect of timing and duration of folate restriction on mTOR and
DNA methyltransferases.

It is of utmost importance to continue to investigate the relationship between folate and
cancer. It would be tempting to accept the opinion of the majority and presume that folate can do
no harm. However, the magnitude of evidence that points in the other direction has become
overwhelming. Future studies should focus on attempting to duplicate the results in other lab
models and genetic backgrounds. Proteomics, metabolomic, and epigenetic studies should be
conducted to further understand the dynamics and adaptation that link folate to various signaling
pathways involved in cancer. Establishing accurate and standardized folate requirements for
animal studies is necessary to draw parallels and compare results. Most importantly, establishing
the proper human requirements without attempting to generalize and enforce the recommendation
on all subsets of the population is warranted. The human population is heterogeneous with varying
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nutritional requirements and subject to diverse environmental and genetic influences. In the era of
personalized medicine, we should scrutinize generalized public health policies and personalize
nutrition in the same manner we personalize medicine.
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TIMING AND DURATION OF FOLATE RESTRICTION DIFFERENTIALLY
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Colorectal cancer (CRC) constitutes a major burden on the healthcare system as the second
most commonly diagnosed cancer in the developed world. Dietary folate is considered an
important modulator of colorectal cancer. Folate restriction has been implicated in increasing CRC
incidence by disrupting nucleotide synthesis, Impacting DNA methylation and inducing genetic
instability. Our research shows that the timing and duration of dietary folate restriction can
differentially impact Colorectal cancer initiation. Acclimating mice to folate restriction for 8 weeks
results in a reduced number of preneoplastic lesions compared to mice placed of folate restriction
for 1 week prior to initiating the carcinogenic treatment. Analysis of the mTOR pathway revealed
distinct differences in crucial target proteins between the two conditions. Furthermore, we noted
differences in the expression of key DNA methyltransferases impacting global methylation.
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